

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/007743 A2

- (51) International Patent Classification⁷: C12Q (74) Agent: STEELE, Alan, W.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
- (21) International Application Number: PCT/IB2003/003727 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 17 July 2003 (17.07.2003) (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (25) Filing Language: English (26) Publication Language: English
- (30) Priority Data: 60/396,432 17 July 2002 (17.07.2002) US
- (71) Applicant: COLEY PHARMACEUTICAL GMBH [DE/DE]; Elisabeth-Selbert-Strasse 9, 40764 Langenfeld (DE).
- (72) Inventors; and (75) Inventors/Applicants (*for US only*): WAGNER, Hermann [DE/DE]; Kaagangerstrasse 36, 82279 Eching (DE). KRETZSCHMAR, Hans [DE/DE]; Nelkenweg 5a, 82515 Wolfratshausen (DE). SETHI, Shneh [DE/DE]; Platanen Strasse 56, 81377 Muenchen (DE).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/007743 A2

(54) Title: USE OF CPG NUCLEIC ACIDS IN PRION-DISEASE

(57) Abstract: Methods are provided which are useful in the treatment of prion diseases and other protein deposit diseases, including, for example, post-exposure prophylaxis against the development of iatrogenic Creutzfeldt-Jakob disease. The methods involve the use of immunostimulatory nucleic acids, including CpG nucleic acids.

- 1 -

USE OF CpG NUCLEIC ACIDS IN PRION DISEASE

Field of the Invention

The instant invention pertains to methods useful in the treatment of prion diseases, including, for example, post-exposure prophylaxis against the development of iatrogenic Creutzfeldt-Jakob disease. The methods involve the use of immunostimulatory nucleic acids.

Background of the Invention

Prion diseases include a number of fatal, neurodegenerative diseases believed to be caused by aggregates of normal protein that is present in an abnormal conformation. The normal protein, prion protein, is usually present in the cell membrane of many tissues, particularly neuronal tissue. The abnormally conformed prion protein is believed to be directly involved in converting normally conformed prion protein into more of the abnormally conformed prion protein, which then self-assembles into aggregates that are damaging to neuronal tissue anatomy and function.

At least some of the prion diseases are transmissible. However, unlike bacteria, viruses, fungi, parasites, and other replicating pathogens, transmissible prions are simply proteins; they are transmissible without any accompanying nucleic acid. For reasons that are not yet fully understood, the abnormally conformed prion proteins normally do not induce an immune response. Thus, exposure of a healthy individual to abnormally conformed prion protein can initiate a prion disease that can go unchecked by the immune system.

Exposure to abnormally conformed prion protein thus represents a health risk to susceptible individuals. Such individuals include humans and non-humans, principally cows and sheep. Exposure can come about through contact with prion-diseased animal products through ingestion, iatrogenic or work-related exposure, transplantation, and administration of pharmaceutical preparations.

Summary of the Invention

The instant invention is based in part on the unexpected discovery by the inventors that administration of immunostimulatory nucleic acid to a subject that is exposed to abnormally conformed prion protein is an effective treatment of prion disease. The immunostimulatory nucleic acid effectively delayed and even prevented disease in animals

- 2 -

administered very large doses of prion-diseased brain homogenates that uniformly caused fatal disease in all untreated control animals similarly exposed to prion-diseased brain homogenates.

The immunostimulatory nucleic acids are useful in the treatment of prion diseases, including Creutzfeldt-Jakob disease (CJD), bovine spongiform encephalopathy (BSE), and scrapie. The methods of the invention are also useful for the study of these diseases, for instance, in animal models. The methods will also be useful for developing an understanding of how prion proteins normally fail to elicit an immune response and how an immune response can be elicited and used to treat prion protein disease.

The immunostimulatory nucleic acids are also useful in the treatment of other neurologic diseases involving abnormal protein deposits or aggregates. Such diseases include Alzheimer's disease, which involves deposits of amyloid. The main component of amyloid plaques is amyloid- β peptide (A β), a fibrillar 40-42 amino acid peptide that accumulates extracellularly and causes neuronal death.

In one aspect the invention provides a method for treating a prion disease in a subject. The method involves administering to a subject having or at risk of developing a prion disease a CpG nucleic acid in an effective amount to treat the prion disease. In one embodiment the administering follows exposure of the subject to a prion protein that is associated with a prion disease. In one embodiment the prion disease is a transmissible spongiform encephalopathy (TSE). In one embodiment the subject is a human.

In various preferred embodiments, the prion disease is scrapie, BSE, or a form of CJD. The CJD in one embodiment is iatrogenic CJD (iCJD). In another embodiment the CJD is variant CJD (vCJD). In yet another embodiment the CJD is sporadic CJD.

In one aspect the invention provides a method for inducing an immune response to a prion protein. The method according to this aspect of the invention involves the steps of contacting an antigen-presenting cell (APC) with a prion protein and contacting the APC with a CpG nucleic acid in an effective amount to induce an immune response to the prion protein. In one embodiment the immune response occurs *in vivo*. In one embodiment the immune response occurs *in vitro*. In all embodiments according to this aspect of the invention the APC is preferably chosen from a B cell, a dendritic cell, a macrophage, and a monocyte. In one preferred embodiment the APC is a dendritic cell.

- 3 -

Also according to this aspect of the invention, in one embodiment the APC expresses a Toll-like receptor (TLR) that signals in response to the CpG nucleic acid. It has recently been reported that CpG nucleic acid can specifically induce a particular TLR, designated TLR9, to signal. Accordingly, in one embodiment the TLR is TLR9.

In one embodiment the prion protein includes prion protein:scrapie form (PrP^{Sc}). In another embodiment the prion protein includes a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc} . In yet another embodiment the prion protein includes a derivative of PrP^{Sc} or a derivative of a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc} .

In one embodiment the prion protein is prion protein:scrapie form (PrP^{Sc}). In another embodiment the prion protein is a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc} . In yet another embodiment the prion protein is a derivative of PrP^{Sc} or a derivative of a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc} .

It has been reported that certain CpG nucleic acids are more effective in one species than in another. Accordingly, in preferred embodiments the CpG nucleic acid is optimized for use in a species of the subject.

It has also been reported that CpG nucleic acids appear to fall into different classes based on certain structural features as well as their function. At least three classes are believed to exist, denoted Class A, Class B, and Class C. In one embodiment the CpG nucleic acid is a class B CpG nucleic acid. In one embodiment the CpG nucleic acid is a class A CpG nucleic acid. In one embodiment the CpG nucleic acid is a class C CpG nucleic acid.

These and other features of the invention are described in greater detail in connection with the detailed description of the invention.

Detailed Description of the Invention

A major step in the study of prions and the diseases that they cause was the discovery and purification of a protein designated prion protein (PrP). Bolton et al. (1982) *Science* 218:1309-11; Prusiner SB et al. (1982) *Biochemistry* 21:6942-50; McKinley MP et al. (1983) *Cell* 35:57-62. Complete prion protein-encoding genes have since been cloned, sequenced and expressed in transgenic animals. PrP^{C} is encoded by a single-copy host gene (Basler K et

- 4 -

al. (1986) *Cell* 46:417-28) and is normally found at the outer surface of neurons. Prion diseases are accompanied by the conversion of PrP^C into a modified form called PrP^{Sc}.

The scrapie isoform of the prion protein (PrP^{Sc}) is thought necessary for both the transmission and pathogenesis of the transmissible neurodegenerative diseases of animals and humans. See Prusiner SB (1991) *Science* 252:1515-22. The most common prion diseases of animals are scrapie of sheep and goats and bovine spongiform encephalopathy (BSE; "mad cow disease") of cattle. Wilesmith J et al. (1991) *Microbiol Immunol* 172:21-38. Four prion diseases of humans have been identified: (1) kuru, (2) Creutzfeldt-Jakob disease (CJD), (3) Gerstmann-Sträussler-Scheinker (GSS) syndrome, and (4) fatal familial insomnia. Gajdusek DC (1977) *Science* 197:943-60; Medori et al. (1992) *N Engl J Med* 326:444-9.

Most CJD cases are sporadic, but about 10-15% are inherited as autosomal dominant disorders that are caused by mutations in the human PrP gene. Hsiao et al. (1990) *Neurology* 40:1820-7; Goldfarb et al. (1992) *Science* 258:806-8. Iatrogenic CJD has been caused by human growth hormone derived from cadaveric pituitaries as well as dura mater grafts. Brown et al. (1992) *Lancet* 340:24-7. Despite numerous attempts to link CJD to an infectious source such as the consumption of meat from scrapie-infected sheep, none has been identified to date (Harries-Jones et al. (1988) *J Neurol Neurosurg Psychiatry* 51:1113-9) except in cases of iatrogenically induced disease. On the other hand, kuru, which for many decades devastated the Fore and neighboring tribes of the New Guinea highlands, is believed to have been spread by infection during ritualistic cannibalism.

The major component of purified infectious prions, designated PrP 27-30, is the proteinase K resistant core of a larger native protein PrP^{Sc} which is the disease causing form of the ubiquitous cellular protein PrP^C. PrP^{Sc} is found only in scrapie infected cells, whereas PrP^C is present in both infected and uninfected cells implicating PrP^{Sc} as the major, if not the sole, component of infectious prion particles. Since both PrP^C and PrP^{Sc} are encoded by the same single copy gene, great effort has been directed toward unraveling the mechanism by which PrP^{Sc} is derived from PrP^C. Central to this goal has been the characterization of physical and chemical differences between these two molecules. Properties distinguishing PrP^{Sc} from PrP^C include low solubility (Meyer RK et al. (1986) *Proc Natl Acad Sci USA* 83:2310-4), poor antigenicity (Kascsak RJ et al. (1987) *J Virol* 61:3688-93; Serban D et al. (1990) *Neurology* 40:110-7), protease resistance (Oesch B et al. (1985) *Cell* 40:735-46), and polymerization of PrP 27-30 into rod-shaped aggregates which are very similar, on the

- 5 -

ultrastructural and histochemical levels, to the PrP amyloid plaques seen in scrapie-diseased brains (Prusiner SB et al. (1983) *Cell* 35(2 Pt 1):349-58). By using proteinase K it is possible to denature PrP^C but not PrP^{Sc}. To date, attempts to identify any post-translational chemical modifications in PrP^C that lead to its conversion to PrP^{Sc} have proven fruitless. Stahl N et al. (1993) *Biochemistry* 31:5043-53. Consequently, it has been proposed that PrP^C and PrP^{Sc} are in fact conformational isomers of the same molecule.

Conformational description of PrP using conventional techniques has been hindered by problems of solubility and the difficulty in producing sufficient quantities of pure protein. However, PrP^C and PrP^{Sc} are conformationally distinct. Theoretical calculations based upon the amino acid sequences of PrPs from several species have predicted four putative helical motifs in the molecule. Experimental spectroscopic data would indicate that in PrP^C these regions adopt alpha-helical arrangements, with virtually no beta-sheet. Pan et al. (1993) *Proc Natl Acad Sci USA* 90:10962-6). In dramatic contrast, in the same study it was found that PrP^{Sc} and PrP 27-30 possess significant beta-sheet content, which is typical of amyloid proteins. Moreover, studies with extended synthetic peptides, corresponding to PrP amino acid residues 90-145, have demonstrated that these truncated molecules may be converted to either alpha-helical or beta-sheet structures by altering their solution conditions. The transition of PrP^C to PrP^{Sc} requires the adoption of beta-sheet structure by regions that were previously alpha-helical.

In general, scrapie infection fails to produce an immune response, with host organisms being tolerant to PrP^{Sc} from the same species. Polyclonal anti-PrP antibodies have been raised in rabbits following immunization with large amounts of Syrian hamster PrP 27-30. Bendheim PE et al. (1985) *Proc Natl Acad Sci USA* 82:997-1001; Bode L et al. (1985) *J Gen Virol* 66:2471-8. Similarly, a handful of anti-PrP monoclonal antibodies have been produced in mice. Kascsak RJ et al. (1987) *J Virol* 61:3688-93; Barry RA et al. (1986) *J Infect Dis* 154:518-21. These antibodies are able to recognize native PrP^C and denatured PrP^{Sc} from both Syrian hamsters and humans equally well, but do not bind to murine PrP. Unsurprisingly, the epitopes of these antibodies were mapped to regions of sequence containing amino acid differences between Syrian hamster and murine PrP. Rogers et al. (1991) *J Immunol* 147:3568-74.

The DNA sequence of the human, sheep and cow PrP genes have been determined, allowing, in each case, the prediction of the complete amino acid sequence of their respective

- 6 -

PrP proteins. The normal amino acid sequence which occurs in the vast majority of individuals is referred to as the wild-type PrP sequence. This wild-type sequence is subject to certain characteristic polymorphic variations. In the case of human PrP, two polymorphic amino acids occur at residues 129 (Met/Val) and 219 (Glu/Lys). Sheep PrP has two amino acid polymorphisms at residues 136 and 171, while bovine PrP has either five or six repeats of an eight amino acid motif sequence (octarepeats) in the amino terminal region of the mature prion protein. While none of these polymorphisms are of themselves pathogenic, they appear to influence prion diseases. Distinct from these normal variations of the wild-type PrP proteins, certain mutations of the human PrP gene which alter either specific amino acid residues of PrP or the number of octarepeats have been identified which segregate with inherited human prion diseases.

For example, sequences of chicken, bovine, sheep, rat, and mouse PrP genes are disclosed and published within Gabriel JM et al. (1992) *Proc Natl Acad Sci USA* 89:9097-101. A sequence for a PrP gene of Syrian hamster is published in Basler K et al. (1986) *Cell* 46:417-28. A PrP gene of sheep is published by Goldmann W et al. (1990) *Proc Natl Acad Sci USA* 87:2476-80. A gene sequence for bovine PrP is published in Goldmann W et al. (1991) *J Gen Virol* 72:201-4. A sequence for chicken PrP gene is published in Harris DA et al. (1991) *Proc Natl Acad Sci USA* 88:7664-8. A PrP gene sequence for mink is published in Kretzschmar HA et al. (1992) *J Gen Virol* 73:2757-61. A human PrP gene sequence is published in Kretzschmar HA et al. (1986) *DNA* 5:315-24. A PrP gene sequence for mouse is published in Locht C et al. (1986) *Proc Natl Acad Sci USA* 83:6372-6. A PrP gene sequence for sheep is published in Westaway D et al. (1994) *Genes Dev* 8:959-69. These publications are all incorporated herein by reference to disclose and describe the PrP gene and PrP amino acid sequences.

Human PrP cDNA (SEQ ID NO:1; GenBank Accession No. M13899)

cggcgccg	agtttctct	tcctcacga	ccgaggcaga	gcagtcatta	tggcgaacct	60
tggctgtgg	atgtctggtc	tctttgtggc	cacatggagt	gacctgggcc	tctgcaagaa	120
gcggccgaa	gctggaggat	ggaacactgg	ggcagccga	tacccggggc	aggcagccc	180
tggaggcaac	cgttaccac	ctcagggcgg	tggtggtgg	ggcagccctc	atggtgtgg	240
ctggggcag	cctcatggtg	gtggctgggg	gcagccccat	gttgtggct	ggggacagcc	300
tcatgggtt	ggctgggttc	aaggagggtgg	cacccacagt	cagtggaca	agccgagtaa	360
gcaaaaaacc	aacatgaagc	acatggctgg	tgctgcagca	gctggggcag	tgtgggggg	420
ccttggcggc	tacatgtgg	gaagtgcatt	gagcagggccc	atcatacatt	tccgcagtga	480
ctatgaggac	cgttactata	gtgaaaacat	gcaccgttac	cccaaccaag	tgtactacag	540
gcccattggat	gagtacagca	accagaacaa	ctttgtgcac	gactgcgtca	atatcacaat	600
caagcagcac	acggcaccca	caaccaccaa	gggggagaac	ttcaccgaga	ccgacgttaa	660
gatgatggag	cgcgtggttg	agcagatgtg	tatcacccag	tacgagaggg	aatctcaggc	720

- 7 -

ctattaccag	agaggatcga	gcatggctt	cttcttcctt	ccacctgtga	tcctcctgat	780
ctcttcctc	atcttcctga	tagtggatg	aggaaggct	tcctgtttc	accatcttc	840
taatctttt	ccagctttag	ggaggcggt	tccacctga	gccctttag	tgggtgtgc	900
tcactttt	ttctctttt	gtccccgata	ggctaataa	tacccttgc	actgatggc	960
actggaaaac	atagagtata	cctgagatgc	tggtaagcc	cccttgcatt	gagttcatca	1020
tgagccgtt	ctaatgccag	gccagaaaaa	gtataacagc	aaataaccat	tggtaatct	1080
ggacttattt	ttggacttag	tgcaacaggt	tgaggctaaa	acaaaactca	gaacagtctg	1140
aaatacctt	gcctggatcc	ctctggctcc	ttcagcagct	agagctcagt	atactaatgc	1200
cctatcttag	tagagatttc	atagctattt	agagatattt	tccattttaa	gaaaacccga	1260
caacatttt	gccagggtt	ttaggaggcc	acatgatact	tattaaaaaa	aatccttagag	1320
atcttagct	cttgggatgc	aggctcagcc	cgctggagca	tgagctctgt	gtgtaccgag	1380
aactgggtg	atgtttact	tttcacagta	tgggtcacac	agcagctgtt	caacaagagt	1440
aaatattgtc	acaacactga	acctctggct	agaggacata	ttcacagtg	acataactgt	1500
aacatataatg	aaaggcttct	gggacttgaa	atcaaatgtt	tgggaatgg	gcccttggag	1560
gcaacctccc	attttagatg	ttttaaggac	cctatatgt	gcattcctt	ctttaaacta	1620
tagtaatta	aggcagctga	aaagtaaattt	gccttctaga	cactgaaggc	aatctcctt	1680
tgtccattt	cctggaaacc	agaatgattt	tgacatacag	gagagctgca	gttgtgaaag	1740
caccatcatc	atagaggatg	atgttaattt	aaaatggtca	gtgtgcaaag	aaaagaactg	1800
cttgcattt	tttattttctg	tctcataatt	gtcaaaaacc	agaatttagt	caagttcata	1860
gttctgtta	ttggctttt	aatcaaagaa	tagggagaca	atctaaaaaa	tatcttaggt	1920
tggagatgac	agaaatatga	ttgatttgaa	gtggaaaaaa	aaattctgtt	aatgttaatt	1980
aaagtaaaat	tattccctga	attgtttgt	attgtcacct	agcagatatg	tattactttt	2040
ctgcaatgtt	attattggct	tgcaacttgc	gagttatctat	gtaaaaatat	atatgtat	2100
aaaatataat	ttgcataatgg	cagactttagg	agttttgttt	agagcagttt	acatctgaag	2160
tgtctaatgc	attaactttt	gtaaaggtact	gaataacttaa	tatgtggaa	accctttgc	2220
gtggccttta	ggcttacaat	gtgcactgaa	tcgtttcatg	taagaatcca	aagtggacac	2280
cattaacagg	tctttgaaat	atgcatgtac	tttatattttt	ctatatttgt	aactttgeat	2340
gttctgttt	tgttatataa	aaaaattgtt	aatgtttaat	atctgactga	aattaaacga	2400
gcgaagatga	gcacc					2415

Mink PrP genomic DNA (SEQ ID NO:2; GenBank Accession No. S46825)

tcattttgtt	ttgtttgtt	ttgtttgcag	ataagccatc	atggtgaaaa	gccacatagg	60
cagctggctc	ctggttctt	ttgtggccac	atggagtgac	attggcttct	gcaagaagcgc	120
gccaaggct	ggaggagct	ggaacactgg	ggggagccga	tacccaggcc	aggcagtc	180
tggaggcaac	cgctaccac	cccagggtgg	ttggggctgg	ggccagcccc	acgggggtgg	240
ctggggacag	ccccacgggg	gtggctgggg	tcaagccac	gggggtggct	ggggacagcc	300
gcatggtggc	ggtggtctgg	gtcaagggtgg	ttggagccac	gttcagtgg	gcaagccag	360
taagcccaa	accaacatga	agcatgtggc	gggagccgca	gcagccgggg	cggtcggtgg	420
gggcctgggc	ggctacatgc	ttggggagcgc	catgagcagg	cccccttattc	attttggcaa	480
cgactatgag	gaccgtact	accgtggaa	catgtaccgc	taccccaacc	aagtgtacta	540
caagccgggt	gatcgttaca	gcaaccagaa	caacttgcgt	catgactgc	tcaacatcac	600
ggtcaagcag	cacacgggt	ccaccaccac	caaggccgag	aacttcacgg	agaccgacat	660
gaagatcatg	gagcgcgtgg	tggagcagat	gtgtgtcacc	cagtaccagc	gagagtccga	720
ggcttactac	cagagggggg	cgagcgcct	cctttctcg	ccccctcccg	tgtatccctt	780
catctactg	ctcattctcc	tgatagtggg	ataggatgg	ccttccatt	ctctccatcg	840
tttcacctt	ttacaggtt	ggggaggggg	tgtctacca	cagccctgt	tggtgtgt	900
cteattcttg	tttctcttta	tcacccatag	gtaatcccc	ttggccctga	tgccctggg	960
aaatgttagag	cagacccagg	atgttattt	tcaagcccc	catgtgttgg	agtccttcag	1020
gggccaatgc	tagtgcaggg	ctgagaataa	cagcaatac	tcattgttgc	acctagggt	1080
gctttttgt	tgtgttgtc	tagtgcagct	gaccgaggt	aaaacaattt	tcaaaacagt	1140
tttcaaatac	ctttgcctgg	aaacctctgg	ctcctgtgc	agctagagct	cagtacatta	1200
atgtcccatc	ttagccgtt	tttcatagca	acttggggaa	gttttctcc	ccactctaaa	1260
agaacgcgt	tgcacttccc	tgtgcataa	acatttctgc	caaatttgc	aggaggccac	1320
atgatattca	ttcaaaaagc	aaaactagaa	accctttgc	cttggacgc	agcccgccct	1380
gctaggagca	ccaaactggg	gcatgtgtt	gatttgc	gcgtggct	tgccgcagcc	1440
gaggtgttca	gcgttaatat	tgtgcacgc	ctagacccat	gcagaggatg	tttgcacagg	1500
gaatgaacat	aatcaacagt	gcgaaaatgc	tacaaaaat	cccacactgg	ggagcagtgt	1560
ccttggaggc	aagttttttt	cctttggga	cattaaagc	cccttatatgt	ggcattccctt	1620

- 8 -

```
tcttcgtaa cctaaactat agataattaa ggcatgtaaa aattgaactt cttccaggc 1680
ccaaagacca aatctttgtt cacttacctg gaaaccagaa tgatggatc acagagggaa 1740
gtcagctgt taaaataacc ctcatcttag aagattgc aatggagaaa acatccgt 1800
gacaaaaatg atcgcatttc ttcatgtct tcctgtattt gacagaaaacc agaattatgt 1860
caagtccatg tttctataat cagctttgtatc aatggagaaa ggaagtcac ccaaaaaaaaa 1920
aaaagaaaata ccttaggtca cccatgacag aaataccat tcaggttata aaaaagggaa 1980
tctgttaact gttatgtttaa taaggcaaaa ttatgtccg gattgttgc tatcatcagc 2040
tagcagataa attagcatcc tgcaatgttc cggcttgcg ctgtgcgggt atttgatgtt 2100
aaaaaaaaattt attatataat ttgtgtatga caaactttaga agttttgtt agaggaggtt 2160
acatctgata tatctaattgc accaccgtt ttggaaaggta ctaaataactt aatatgttaga 2220
aatcccttttgc cgtggccctc aggcttacac gtgcactgaa tagtttgta tgatagagcc 2280
catgtggctc tcgaaatatgt catgtactttt atatttctat tatttgcac tggcatgt 2340
cttgatataaa aaatgtataaa acatcgaaac tcttgacttag aattaaacag gaactgagtg 2400
tgtcccatgt gtttgcagtg acattcacca ccgcaccctg tgttgg 2446
```

Syrian Hamster PrP cDNA (SEQ ID NO:3; GenBank Accession No. M14054)

```
tcgaaaatct cccttttag caatttttg ctccatgtt ttcagcaatt gctttctcg 60
tccatttaggc aacctttcat tttctcacct tccccattat gtaacggggg caatgggttc 120
tggaccagtc ttccattaaa gatgatgtt atagtcgggt agccgtca gggagtgatg 180
acacctgggg gcggtttaaa ccgtacaatc ccttaaaccac gtctggagcg gtactcatt 240
tccccaggga gaagtggccg ggcatttggt gggcacgacg caagccccgc cccaccccagc 300
ccggccccgc cctgttaccc ctccctgactc actggcccccgc ccgtcccccc gggcggtccg 360
agcagcagac cgagaaggca catcgatgtcc actcgatcgcc tcgggtggcag gtaagcggct 420
tctgaagcct gggcccgggg aggggtgtgg agccaggccct cggtaagcct tcggcttccc 480
agagccaagc ccggcttact ccggctctcg gggcgcttag gccgcggggc tgaggttgag 540
tctggctggg aggtgaccgc gcaccccgag ccgcgcgtct ctttgaggga ccgaaccccc 600
ggagaggcga ggagccatcc ctccctcccg agcccggtcc acccccaagag tcgctcgggg 660
atggggatgtt gggatgggg tggcatctt tgactgtcg tttgtgtttt ctctctctt 720
tgtaatagct acagcgaaca taattttacc cagggttcca ccgtggctc gtccgtccctc 780
ggcatctctc agtccagtagt acatccaaagg 810
```

Sheep PrP cDNA (SEQ ID NO:4; GenBank Accession No. AJ223072)

```
atggtaaaaa gcccacatagg cagttggatc ctgggtctct ttgtggccat gtggagtgac 60
gtggccctct gcaagaaggcg accaaaacct ggcggaggat ggaacactgg ggggagccga 120
tacccgggac agggcagttcc tggaggcaatc cgcttatccac ctcaggggagg ggggtggctgg 180
ggtcagcccc atggaggtgg ctggggccaa cctcatggag gtggctgggg tcagccccat 240
gggtgtggct ggggacagcc acatgggtggt ggaggctggg gtcaaggtgg tagccacagt 300
cagtggaaaca agcccaatggca aacatggaaacg atgtggcagg agtgcgtca 360
gctggagcag tggtaggggg ctttgggtggc tacatgtggt gaaatggccat gggcaggcc 420
cttatacatt ttggcaatga ctatggggc cgttactatc gtggaaatcat gtaccgttac 480
cccaaccaag tgtactacag accagtggat cagtatgtt accagaacaa ctttgcacat 540
gactgtgtca acatcacatg caagaaacac acatgcacca ccaccaccaa gggggagaac 600
ttcacccggaa ctgacatcaa gataatgggg cggatgtggtgg agccaaatgtt catcaccac 660
taccagagag aatcccggc ttattaccaa agggggggcaa gtgtgtatctt cttttcttcc 720
cctctgtga ttctctctat ctcttcttc attttctca tagggata gggcaacact 780
ttctgttttc attatcttct taatcttgc cagggtgggg gagggaggtt ctacatgtcag 840
ccctgttagt gtgggtgtctc atttcttgc tctcttctgt tacatgtata ataataaccct 900
tggcgcttac agcaactggaa aatgacaagc agacatgaga tgctgtttat tcaagtcacca 960
tttagcttgc atttctatgtt cccatcttag cagtgtttt gttagcaattt tctcttctgt 1020
ttcaagaaca cctgactaca ttcccttgc ggaatagcat ttctgccaag tctggaaagg 1080
ggccacataa tatttcatca aaaaaacaaa actggaaatc ctttagttcat agacccagg 1140
tccaccctgt tgagagcatg tggctgtgt ctgcagagaa ctataaaggaa tatttctgtat 1200
tttgcaggtt acatttgcag gtaacacagc catctattgc atcaagaatg gatattcatg 1260
caaccttgc cttatggggca gaggacatct tcacaaggaa tgaacataat acaaaggctt 1320
ctgagactaa aaaattccaa catatggaaag aggtggccctt ggtggcagcc ttccatttt 1380
tatgttttaaag caccttcaag tgatattcct ttctttgtatc acataaagta tagataatta 1440
aggtagtacca attaaactac cttcttagaca ctgagagcaa atctgtgtt tatctggaaac 1500
```

- 9 -

Bovine PrP cDNA (SEQ ID NO:5; GenBank Accession No. X55882)

atggtaaaaa	gccacatagg	cagttggatc	ctgggtctct	ttgtggccat	gtggagtgac	60
gtgggcctct	gcaagaagcg	accaaaacct	ggaggaggat	ggaacactgg	ggggagccga	120
tacccagcac	agggcagtcc	tggaggcaac	cgttatccac	ctcaggggagg	gggtggctgg	180
ggtcagcccc	atggaggtgg	ctggggccag	cctcatggag	gtggctgggg	ccagccatcat	240
ggaggtggct	ggggtcagcc	ccatgggtgt	ggctggggac	agccacatgg	ttgtggaggc	300
tggggtaaag	gtggtaccca	cggtcaatgg	aacaacccca	gtaagccaaa	aaccaacatg	360
aagcatgtgg	caggagctgc	tgcagctgga	gcagtggtag	ggggccttgg	tggctacatg	420
ctggaaagt	ccatgagcag	gcctttata	catttggca	gtgactatga	ggaccgttac	480
tatcgtaaa	acatgcaccc	ttaccccaa	caagtgtact	acaggccagt	ggatcagtat	540
agtaaccaga	acaactttgt	gcatgactgt	gtcaacatca	cagtcaagga	acacacagtcc	600
accaccacca	ccaagggga	gaacttcacc	gaaactgaca	tcaagatgat	ggagcgagtg	660
gtggagcaaa	tgtcattac	ccagtaccag	agagaatccc	aggcttatta	ccaaacgaggg	720
gcaagtgtga	tcctttctc	ttccccctct	gtgatcttcc	tcatctttt	cctcattttt	780
ctcatagtag	gatag					795

- 10 -

Chicken PrP cDNA (SEQ ID NO:6; GenBank Accession No. M61145)

gaattccctc	ggcagccagc	tcctccctct	cgctatTTtat	tccttTctcc	ccccccTacg	60
ctggatctgg	atcatctcaa	gccgagcggt	gacggcttct	tggatcgctc	atacataaaat	120
atctgtgagt	cagaggaagc	aaccaccgac	ccaaagacct	caccccggc	catggctagg	180
ctcctcacca	cctgctgcct	gctggccctg	ctgctcgccg	cctgcaccga	cgtcgccctc	240
tccaaagaagg	gcaaaggcaa	acccagtgg	gggggttggg	gcccggggag	ccatcgccag	300
cccgactacc	cccgccagcc	gggctaccct	cataacccaa	ggtaaaaaaa	taacccaggg	360
taccccccaca	acccctggcta	tcccccataac	cccgctacc	cccagaaccc	tggctacccc	420
cataacccag	gttacccagg	ctggggtcaa	gctacaacc	catccagcgg	agaagttac	480
cacaaccaga	agccatggaa	accccccää	accaacttca	agcacgtggc	gggggcagca	540
gcggcgggtg	ctgtgggggg	gggcttgggg	gctacgcca	tggggcgcgt	tatgtcaggg	600
atgaactacc	acttcgatag	acccgatgag	taccgatgg	ggagtgagaa	ctcggcgcgt	660
tatcccaacc	gggtttacta	ccgggattac	agcagcccc	tgccacagga	cgtttcgtg	720
gcccattgt	ttaacatcac	agtactgag	tacagcattt	gcccgtctgc	caagaagaac	780
acctccgagg	ctgtggcggc	agcaaaacaa	acggaggtgg	agatggagaa	caaagtgg	840
acgaaggtga	tccgcgagat	gtgcgtcag	cagtaccgcg	agtaccgcct	ggcctcggc	900
atccagctgc	accctgctga	cacctggctc	gccgtcctcc	tcctcctct	caccaccctt	960
tttgcctatgc	actgatggga	tgccgtgccc	cgccctgtg	gcagtgagat	gacatcggt	1020
ccccgtgccc	acccatgggg	tgttcttgc	cctcgctttt	gtccatcttt	ggtgaagatg	1080
tccccccgc	gcctccccc	aggctctgat	ttgggcaat	gggagggat	tttgtcctgt	1140
cctggctgt	gcaggacggc	tgctgggtgg	ggagtggat	gccccaaaaa	tggccttac	1200
cacttcctcc	tccttcctt	ttctgggccc	gagatatggg	ctcgccacgc	ccttattgtc	1260
cctgcaagag	cgtatctgaa	aatccctttt	gctaacaac	agggttttac	ctaatctgt	1320
tagccccagt	gacagcagag	cgcctttccc	cagggcacac	caacccaa	ctgaggtgt	1380
tggcagccac	acgtccccatg	gaggctgtat	gtttttgggg	cgtcccaac	aacaccctgg	1440
gctactgagg	tgcaattgt	gtctttat	ctgccaatcc	caacccatcc	gtgttagatag	1500
gaactgcctg	ctctgcattt	tgcatgtgc	aaacacccctc	tgccgcagcg	ccccccaaat	1560
agagtattt	gggaatagt	aggctgaagc	cacagcagct	tgggattggg	ctcatcatat	1620
caatccatg	tgctttgtt	ccagtgagc	ctactgtcccc	ttttatagcc	tggccagagg	1680
aagggagcgc	tgctaaatgc	ccaaaaaggt	aactactgag	aaaaggttat	ttcaatgtat	1740
gatagagaac	gagtgcattt	cgcacagatc	agccatgggg	gcatcgttt	ccatcagccc	1800
caaaacccaa	aggatgtctaa	aatgcagcc	aaggggaaatc	aagcacgcag	ggaaggactt	1860
gaatcagctc	aactggattt	aatatggccaa	aggcatgagt	agaacaaacg	gcaagggat	1920
gctggagatc	cacccctgt	gagcaaattt	ttcgtatgcag	ccaaatggaa	tattgttct	1980
tgtgttctcg	ttgtgtctga	tgtgtacata	ggctgtagea	tatgtaaaat	tacacgtgt	2040
aagctgctcg	caccgcgtat	agctaataatg	tatcatgtat	gtgggcactg	aatgccaccg	2100
ttggccatac	ccaacccgttcc	taaaacgattt	tcacgtcgct	gtaacttaag	tggagataca	2160
ctttcagtat	attcagcaaa	aggaattc				2188

Mouse PrP cDNA (SEQ ID NO:7; GenBank Accession No. M13685)

aattccttca	gaactgaacc	atttcaacc	agctgaagca	ttctgccttc	ctagtggta	60
cagtccaaatt	taggagagcc	aagcagacta	tcagtcata	tggcgaacct	tggctactgg	120
ctgctggccc	tctttgtgac	tatgtggact	gatgtggcc	tctgcaaaaa	gcccggccaaag	180
cctggagggt	ggaacaccgg	tggagccgg	tatccggggc	agggaaagccc	tggaggcaac	240
cgttacccac	ctcagggtgg	cacccgggg	cagccccacg	gtggggctg	gggacaaccc	300
catgggggca	gctggggaca	acccatgtt	ggtagttggg	gtcagccca	tggcgttga	360
tggggccaa	gagggggatc	ccataatcag	tggacaac	ccagcaaacc	aaaaaccaac	420
ctcaagcatg	tggcaggggc	tgcgtcagct	ggggcagtag	tggggggct	tgggtggctac	480
atgctgggaa	gcgcgcgtg	cacccggat	atccatTTT	gcaacgactg	ggaggaccgc	540
tactaccgt	aaaacatgt	ccgcattcc	aaccaagtgt	actacaggcc	agtggatcag	600
tacagcaacc	agaacaactt	cgtgcacgac	tgcgtcaata	tcacccatcaa	gcagcacacg	660
gtcaccacca	ccaccaaggg	ggagaacttc	acccgagaccg	atgtgaagat	gatggagcgc	720
gtgggtggac	agatgtgcgt	caccctgtac	cagaaggagt	cccaggccta	ttacgacggg	780
agaagatcca	gcagcaccgt	gttttctcc	tccctcttgc	tcatcctct	catctccttc	840
ctcatcttcc	tgatgtggg	atgagggagg	cttctctgt	tgttcttgc	cattctcg	900
gtctaggctg	ggggaggggt	tatccacctg	tagctttc	aattgaggtg	gttctcattc	960

- 11 -

ttgtttctct	gtgtccccca	taggctaata	cccctggcac	tgatggcc	tggaaaatgt	1020
acagtagacc	agttgcctt	tgcttcagg	cccttgatg	gagtctgtc	tcagccagt	1080
ctaacaccgg	gccaataaga	atataacacc	aaataactgc	tggctagtt	gggcttgg	1140
ttggctagt	gaataaaatc	tggtgtatcc	cctgacttgt	acccagagta	caaggtgaca	1200
gtgacacatg	taacttagca	taggcaaagg	gttctacaac	caaagaagcc	actgtttgg	1260
gatggcgccc	tggaaaacag	cctcccac	gggatagcta	gagcatccac	acgtggaatt	1320
ctttcttac	taacaaacga	tagctgattt	aaggcaacaa	aaaaaaaaaa	atcaaattgt	1380
cctactgacg	ttgaaagcaa	acctttgtc	attcccagg	cactagaatg	atctttagcc	1440
ttgcttgat	tgaacttagga	gatcttgact	ctgaggagag	ccagccctgt	aaaaagctg	1500
gtccctctgt	gacgggaggg	atggtaagg	tacaaaggct	agaaacttga	gttcttcat	1560
ttctgtctca	caattatcaa	aagctagaat	tagttctgc	cctatgtt	tgtacttcta	1620
tttgaactgg	ataacagaga	gacaatctaa	acattctt	aggctgcaga	taagagaagt	1680
aggctccatt	ccaaagtgg	aaagaaaattc	tgcttagcatt	gtttaaatca	ggcaaaaattt	1740
gttcctgaag	ttgctttta	ccccacgaga	cataaaactgc	gatagcttca	gcttgcactg	1800
tggattttct	gtatagaata	tataaaacat	aacttcaagc	ttatgtt	ttttaaaac	1860
atctgaagta	tgggacgccc	tggccgttcc	atccagtact	aatgtttac	cgtgtgaccc	1920
ttgggcttc	agcgtgact	cagtccgta	ggattccaaa	gcagaccct	agctggtctt	1980
tgaatctgca	tgtacttca	gttttctata	tttgcata	tgcattt	ttgtttgtc	2040
atataaaaag	tttataaaatg	tttgcata	gactgacatt	aatagaagc	tatgatg	2097

Sheep PrP cDNA (SEQ ID NO:8; GenBank Accession No. X79912)

gcagagaagt	catcatggtg	aaaagccaca	taggcagttt	gatcctgg	ctctttgtgg	60
ccatgtggag	tgacgtgggc	ctctgcaaga	agcgcacaaa	acctggcga	ggatggaaaca	120
ctggggggag	ccgataccgg	ggacaggcga	gtcctggagg	caaccgcata	ccacctcagg	180
gaggggggtgg	ctggggtcag	ccccatggag	gtggctgggg	ccaacccat	ggaggtggct	240
ggggtcagcc	ccatgggtgg	ggctgggac	agccacatgg	tggtgaggc	tgggtcaag	300
gtggtagcca	cagtcaatgg	aaacaagccca	gtaagccaaa	aaccaacatg	aagcatgtgg	360
caggagctgc	tgcagctgga	gcagtggtag	ggggccttgg	tggctacatg	ctgggaagtg	420
ccatgagcag	gcctttata	cattttggca	atgactatga	ggaccgttac	tatcgtgaaa	480
acatgtaccg	ttaccccaac	caagtgtact	acagaccagt	ggatcgttat	agtaaccaga	540
acaactttgt	gcatgactgt	gtcaacatca	cagtcaagca	acacacagtc	accaccacca	600
ccaaggggga	gaacttcacc	gaaactgaca	tcaagataat	ggagcgagt	gtggagcaaa	660
tgtcatcac	ccagtagcc	agagaatccc	aggcttatta	ccaaaggggg	gcaagtgtga	720
tcctcttttc	ttccctctt	gtgatcctcc	tcatctttt	cctcattttt	ctcatagtag	780
gatagggca	acccctgtt	ttt				803

Rat PrP cDNA (SEQ ID NO:9; GenBank Accession No. NM_012631)

atggcgaacc	ttggctactg	gctgctggcc	ctctttgtga	ctacatgtac	tgatgttggc	60
ctctgcaaaa	agcggccaaa	gcctggagg	tggaaacactg	gtggaaaggc	gtacccctggg	120
cagggaaagcc	ctggaggccaa	ccgttaccca	cctcagagtg	gtggtaacctg	ggggcagccc	180
catgggtgt	gctggggaca	acccatgtgt	ggtggctggg	gacaacctca	tgggtgtgg	240
tgggtcagc	cccatggcg	gggctggagt	caaggagggg	gtacccatata	tcaatggaaac	300
aagcccagca	agccaaaaac	caaccccaag	catgtggcag	gggctgccc	agctggggca	360
gtagtgggg	gccttgggt	ctacatgtt	gggagtgcca	tgagcaggcc	catgctccat	420
tttggcaacg	actggggagga	ccgcctactac	cgagaaaaaca	tgtaccgtt	ccctaacc	480
gtgtactaca	ggccgggtt	tcagtagcc	aaccagaaca	attctgtc	cgactgtgtc	540
aatatccca	tcaagcagca	tacagtccacc	accaccacca	agggggagaa	cttcacggag	600
accgacgtga	agatgtatgg	gcgtgtgg	gaggagatgt	gcgtcaccc	gtatcagaag	660
gagtcccagg	cctattacga	cgggagaaga	tctagcgcc	tgttttctc	ctccccctc	720
gtgatcctcc	tcatctt	cctcatctt	ctgatctgtt	gatga		765

As used herein, "prion disease" refers to any disease or condition in a subject, the pathogenesis of which involves a prion protein other than PrP^C of the species of the subject.

- 12 -

A prion disease will typically but not necessarily be a transmissible spongiform encephalopathy.

As used herein, “transmissible spongiform encephalopathy” and, equivalently, “(TSE)” shall mean any prion disease that is associated with spongiform encephalopathy and is communicable from one individual to another. As prion diseases can include entities other than TSE, this term refers to at least a subset of all prion diseases. At present TSE includes Creutzfeldt-Jakob disease, kuru, Gerstmann-Sträussler-Scheinker syndrome, fatal familial insomnia, bovine spongiform encephalopathy, and scrapie.

As used herein, “Creutzfeldt-Jakob disease” and, equivalently, “(CJD)” refers to the TSE that naturally occurs in humans. CJD includes sporadic, genetic (familial), and infectious (i.e., variant and iatrogenic) forms. CJD is a well described entity in the medical literature, and until now has been widely believed to be a uniformly fatal neurodegenerative disease for which there is no effective form of treatment.

As used herein, “variant Creutzfeldt-Jakob disease” and, equivalently, “(vCJD)”, also referred to in the literature as new variant Creutzfeldt-Jakob disease (nvCJD), refers to CJD attributable to the BSE prion. It can be distinguished from sporadic CJD not only by the prion involved but also by certain clinical and preclinical features. See Aguzzi A (2000) *Haematologica* 85:3-10; Hill AF et al. (1997) *Nature* 389:448-50; Bruce ME et al. (1997) *Nature* 389:498-501; Will R et al. (1996) *Lancet* 347:921-5.

As used herein, “iatrogenic Creutzfeldt-Jakob disease” and, equivalently, “(iCJD)” refers to any form of CJD that is attributable to work- or treatment-related exposure to prion protein that is associated with CJD.

As used herein, “bovine spongiform encephalopathy” and, equivalently, “(BSE)” shall refer to the TSE that occurs naturally in cows and cattle.

As used herein, “scrapie” refers to the TSE that occurs naturally in sheep and goats, as well as to experimental models of scrapie. Scrapie in sheep has been recognized and described in the literature for over 300 years. For a review, see O’Rourke KI (2001) *Vet Clin North Am Food Anim Pract* 17:283-300.

As used herein, a “prion protein that is associated with a prion disease” refers to any prion protein involved in the pathogenesis of a prion disease. A prion protein that is associated with a prion disease can be a prion found in nature. Alternatively, prion protein that is associated with a prion disease can be a prion protein made de novo or modified from

- 13 -

its natural form through human activity, e.g., by in vitro synthesis, chemical synthesis, chemical derivatization, or genetic alteration. Chemical alteration includes, without limitation, altered glycosylation. In a preferred embodiment, a prion protein that is associated with a prion disease is a prion protein found in nature, e.g., PrP^{Sc}. In one embodiment, a prion protein that is associated with a prion disease is a truncated or genetically modified form of a prion protein found in nature. A genetically modified form of a prion protein found in nature includes a fusion protein involving at least a substantial portion of a prion protein as one component, a prion protein that differs from a prion protein found in nature by one or more conservative amino acid substitutions, and allelic variants of the prion protein found in nature.

Naturally occurring residues can be divided into the following classes based on common side chain properties: (1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr; (3) acidic: Asp, Glu; (4) basic: Asn, Gln, His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe. Thus, for example, conservative amino acid substitutions can involve the exchange of a member from one of these classes for another member from the same class. Non-conservative amino acid substitutions can involve the exchange of a member of one of these classes for a member from another class.

A conservative amino acid substitution can involve a substitution of a native amino acid residue with another residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Conservative amino acid substitutions also encompass non-naturally occurring amino acid residues that are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics, and other reversed or inverted forms of amino acid moieties.

As used herein, "prion protein:scrapie form (PrP^{Sc})" refers to any of a number of naturally occurring, species-specific, proteinase K-resistant forms of prion protein associated with prion disease. Specific examples include, but are not limited to, the following: human PrP^{Sc} having an amino acid sequence provided by SEQ ID NO:10; bovine PrP^{Sc} having an amino acid sequence provided by SEQ ID NO:11; bovine PrP^{Sc} having an amino acid sequence provided by SEQ ID NO:12; ovine PrP^{Sc} having an amino acid sequence provided by SEQ ID NO:13; ovine PrP^{Sc} having an amino acid sequence provided by SEQ ID NO:14; and murine PrP^{Sc} having an amino acid sequence provided by SEQ ID NO:15.

- 14 -

Human PrP^{Sc} (SEQ ID NO:10; GenBank Accession No. AAE81600)

MANLGWCMLV LFVATWSDLG LCKKRKPKPG WNTGGSRYPG QGSPGGNRYP PQGGGGWGQP	60
HGGGWGQPHG GGGWQPHGGG WGQPHGGGW QGGGTHSQWN KPSKPKNMKG HMAAGAAAAGA	120
VVGGLGGYML GSAMSRPIIH FGSDYEDRYY RENMHRYPNQ VYYRPMDEYS NQNNFVHDCV	180
NITIKQHTVT TTTKGENFTE TDVKMMERVV EQMCITQYER ESQAYYQRGS SMVLFSSPPV	240
ILLISFLIFL IVG	253

Bovine PrP^{Sc} (SEQ ID NO:11; GenBank Accession No. AAE81601)

MVKSHIGSWI LVLFVAMWSD VGLCKKRKPK GGWNNTGGSR PGQGSPGGNR YPPQGGGGWG	60
QPHGGGWGQP HGGGWGQPHG GGGWQPHGGG WGQPHGGGW QGGGTHGQWN KPSKPKNMKG	120
HVAGAAAAGA VVGGLGGYML GSAMSRPLIH FGSDYEDRYY RENMHRYPNQ VYYRPVDQYS	180
NQNNFVHDCV NITVKEHTVT TTTKGENFTE TDIKMMERVV EQMCVTQYQK ESQAYYDQGA	240
SVILFSSPPV ILLISFLIFL IVG	263

Bovine PrP^{Sc} (SEQ ID NO:12; GenBank Accession No. CAA39368)

MVKSHIGSWI LVLFVAMWSD VGLCKKRKPK GGWNNTGGSR YPGQGSPGGN RYPPQGGGGW	60
GQPHGGGWGQ PHGGGWGQPH GGGWQPHGGG GWGQPHGGGG WGQGGTHGQWN NKPSKPKNMKG	120
KHVAGAAAAG AVVGGGLGGYML GSAMSRPLI HFGSDYEDRY YRENMHRYPN QVYYRPVDQY	180
SNQNNFVHDC VNITVKEHTV TTTTAKGENFT ETDIKMMERVV VEQMCITQYQ RESQAYYQRG	240
ASVILFSSPP VILLISFLIFL IVG	264

Ovine PrP^{Sc} (SEQ ID NO:13; GenBank Accession No. AAE81602)

MVKSHIGSWI LVLFVAMWSD VGLCKKRKPK GGWNNTGGSR PGQGSPGGNR YPPQGGGGWG	60
QPHGGGWGQP HGGGWGQPHG GSGWQPHGGG GWGQGGSHSQ WNKPSPKTNMKG HMAAGAAAAGA	120
GAVVGGGLGGYML GSAMSRPLI HFGNDYEDRY YRENMYRPNQ VYYRPVDQ YSNQNNFVHD	180
CVNITVKQHT VTTTTKGENFT ETDIKIMER VVEQMCITQY QRESQAYYQR GASVILFSSP	240
PVILLISFLI FLIVG	255

Ovine PrP^{Sc} (SEQ ID NO:14; GenBank Accession No. CAA56283)

MVKSHIGSWI LVLFVAMWSD VGLCKKRKPK GGWNNTGGSR YPGQGSPGGN RYPPQGGGGW	60
GQPHGGGWGQ PHGGGWGQPH GGGWQPHGGG GWGQGGSHSQ QWNKPSPKTNMKG HMAAGAAAAGA	120
AGAVVGGGLGGYML GSAMSRPLI HFGNDYEDRY YRENMYRPNQ VYYRPVDQ YSNQNNFVHD	180
DCVNITVKQHT VTTTTKGENFT ETDIKIMER VVEQMCITQY QRESQAYYQR RGASVILFSSP	240
PPVILLISFLI FLIVG	256

Murine PrP^{Sc} (SEQ ID NO:15; GenBank Accession No. AAE81599)

- 15 -

MANLGYWLLA	LFVTMWTDVG	LCKKRPKPGG	WNTGGSRYPG	QGSPGGNRYP	PQGGTWGQPH	60
GGGWGQPHGG	SWGQPHGGSW	GQPHGGGWGQ	GGGTHNQWNK	PSKPKTNLKH	VAGAAAAGAV	120
VGGLGGYMLG	SAMSRPMIHF	GNDWEDRYYR	ENMYRYPNQV	YYRPVDQYSN	QNNFVHDCVN	180
ITIKQHTVTT	TTKGGENFTET	DVKMMERVVE	QMCVTQYQKE	SQAYYDGRRS	SSTVLFSSPP	240
VILLISFLIF	LIVG					254

As used herein, “full-length PrP^{Sc}” refers to a form of PrP^{Sc} that includes all its amino acids as it occurs in nature. It is to be distinguished, for example, from a truncated form of PrP^{Sc}, described elsewhere herein. A full-length PrP^{Sc} can, however, be incorporated into a PrP^{Sc} conjugate or PrP^{Sc} fusion protein.

As used herein, a “derivative of PrP^{Sc}” refers to a chemical or genetic derivative of a naturally occurring form of PrP^{Sc}, including PrP^{Sc} with non-native glycosylation, covalent or non-covalent conjugates formed between PrP^{Sc} and another compound, PrP^{Sc} fusion proteins, and any combination thereof. A “derivative of a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc}” refers to a chemical or genetic derivative of an N-terminally truncated form of PrP^{Sc}, including such truncated forms of PrP^{Sc}: (i) with non-native glycosylation, (ii) as part of a covalent or non-covalent conjugate formed with another compound, (iii) as part of a fusion protein, or (iv) any combination thereof. In preferred embodiments the fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc} refers to a fragment lacking one or more, up to and including all, of the octarepeats (e.g., GGGWGQPH (SEQ ID NO:16) and GGSWGQPH (SEQ ID NO:17)). See Flechsig E et al. (2000) *Neuron* 27:399-408.

A truncated form of a prion protein found in nature is identical in primary sequence to the prion protein found in nature except for the absence of one or more amino acid residues from the N-terminal end, the C-terminal end, or both the N-terminal and the C-terminal ends. Truncated forms can also include deletion mutants, in which an internal sequence is omitted without changing either the N-terminal end or the C-terminal end. In a preferred embodiment, a truncated prion protein lacks one or more, up to and including all, N-terminal octarepeats (e.g., GGGWGQPH and GGSWGQPH). See Flechsig E et al. (2000) *Neuron* 27:399-408.

As used herein, a “fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc}” shall refer to a truncated form of full-length PrP^{Sc} lacking one or more N-terminal amino acids normally present in full-length PrP^{Sc}. In a preferred embodiment, the fragment

- 16 -

lacks one or more, up to and including all, of the octarepeats (e.g., GGGWGQPH and GGSGQPH). See Flechsig E et al. (2000) *Neuron* 27:399-408.

The methods of the instant invention employ immunostimulatory nucleic acids. In the preferred embodiment, the immunostimulatory nucleic acid is a CpG nucleic acid. The terms "nucleic acid" and "oligonucleotide" are used interchangeably to mean multiple nucleotides (i.e., molecules comprising a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymidine (T) or uracil (U)) or a substituted purine (e.g., adenine (A) or guanine (G)). As used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms "nucleic acid" and "oligonucleotide" shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g., genomic or cDNA), but are preferably synthetic (e.g., produced by nucleic acid synthesis).

The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with substitutions or modifications, such as in the bases and/or sugars. For example, they include nucleic acids having backbone sugars that are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have an amino acid backbone with nucleic acid bases).

Nucleic acids also include substituted purines and pyrimidines such as C-5 propyne modified bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymidine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties. Other such modifications are well known to those of skill in the art.

The immunostimulatory oligonucleotides of the instant invention can encompass various chemical modifications and substitutions, in comparison to natural RNA and DNA, involving a phosphodiester internucleoside bridge, a β -D-ribose unit and/or a natural

- 17 -

nucleoside base (adenine, guanine, cytosine, thymine, uracil). Examples of chemical modifications are known to the skilled person and are described, for example, in Uhlmann E et al. (1990) *Chem Rev* 90:543; "Protocols for Oligonucleotides and Analogs" *Synthesis and Properties & Synthesis and Analytical Techniques*, S. Agrawal, Ed, Humana Press, Totowa, USA 1993; Crooke ST et al. (1996) *Annu Rev Pharmacol Toxicol* 36:107-129; and Hunziker J et al. (1995) *Mod Synth Methods* 7:331-417. An oligonucleotide according to the invention can have one or more modifications, wherein each modification is located at a particular phosphodiester internucleoside bridge and/or at a particular β -D-ribose unit and/or at a particular natural nucleoside base position in comparison to an oligonucleotide of the same sequence which is composed of natural DNA or RNA.

For example, the invention relates to an oligonucleotide which comprises one or more modifications and wherein each modification is independently selected from:

- a) the replacement of a phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside by a modified internucleoside bridge,
- b) the replacement of phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a diphospho bridge,
- c) the replacement of a sugar phosphate unit from the sugar phosphate backbone by another unit,
- d) the replacement of a β -D-ribose unit by a modified sugar unit, and
- e) the replacement of a natural nucleoside base by a modified nucleoside base.

More detailed examples for the chemical modification of an oligonucleotide are as follows.

A phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside can be replaced by a modified internucleoside bridge, wherein the modified internucleoside bridge is for example selected from phosphorothioate, phosphorodithioate, NR¹R²-phosphoramidate, boranophosphate, α -hydroxybenzyl phosphonate, phosphate-(C₁-C₂₁)-O-alkyl ester, phosphate-[(C₆-C₁₂)aryl-(C₁-C₂₁)-O-alkyl]ester, (C₁-C₈)alkyl-phosphonate and/or (C₆-C₁₂)-arylphosphonate bridges, (C₇-C₁₂)- α -hydroxymethyl-aryl (e.g., disclosed in WO 95/01363), wherein (C₆-C₁₂)aryl, (C₆-C₂₀)aryl and (C₆-C₁₄)aryl are optionally substituted by halogen, alkyl, alkoxy, nitro, cyano, and where R¹ and R² are, independently of each other, hydrogen, (C₁-C₁₈)-alkyl, (C₆-C₂₀)-aryl, (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl, preferably hydrogen, (C₁-C₈)-alkyl, preferably (C₁-C₄)-alkyl and/or methoxyethyl, or R¹ and R² form, together with

- 18 -

the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain a further heteroatom from the group O, S and N.

The replacement of a phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge (dephospho bridges are described, for example, in Uhlmann E and Peyman A in "Methods in Molecular Biology", Vol. 20, "Protocols for Oligonucleotides and Analogs", S. Agrawal, Ed., Humana Press, Totowa 1993, Chapter 16, pp. 355ff), wherein a dephospho bridge is for example selected from the dephospho bridges formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, methylenedimethyl-hydrazone, dimethylenesulfone and/or silyl groups.

A sugar phosphate unit (i.e., a β -D-ribose and phosphodiester internucleoside bridge together forming a sugar phosphate unit) from the sugar phosphate backbone (i.e., a sugar phosphate backbone is composed of sugar phosphate units) can be replaced by another unit, wherein the other unit is for example suitable to build up a "morpholino-derivative" oligomer (as described, for example, in Stirchak EP et al. (1989) *Nucleic Acids Res* 17:6129-41), that is, e.g., the replacement by a morpholino-derivative unit; or to build up a polyamide nucleic acid ("PNA"; as described for example, in Nielsen PE et al. (1994) *Bioconjug Chem* 5:3-7), that is, e.g., the replacement by a PNA backbone unit, e.g., by 2-aminoethylglycine.

A β -ribose unit or a β -D-2'-deoxyribose unit can be replaced by a modified sugar unit, wherein the modified sugar unit is for example selected from β -D-ribose, α -D-2'-deoxyribose, L-2'-deoxyribose, 2'-F-2'-deoxyribose, 2'-O-(C₁-C₆)alkyl-ribose, preferably 2'-O-(C₁-C₆)alkyl-ribose is 2'-O-methylribose, 2'-O-(C₂-C₆)alkenyl-ribose, 2'-[O-(C₁-C₆)alkyl-O-(C₁-C₆)alkyl]-ribose, 2'-NH₂-2'-deoxyribose, β -D-xylo-furanose, α -arabinofuranose, 2,4-dideoxy- β -D-erythro-hexo-pyranose, and carbocyclic (described, for example, in Froehler J (1992) *Am Chem Soc* 114:8320) and/or open-chain sugar analogs (described, for example, in Vandendriessche et al. (1993) *Tetrahedron* 49:7223) and/or bicyclosugar analogs (described, for example, in Tarkov M et al. (1993) *Helv Chim Acta* 76:481).

A natural nucleoside base can be replaced by a modified nucleoside base, wherein the modified nucleoside base is for example selected from hypoxanthine, uracil, dihydrouracil, pseudouracil, 2-thiouracil, 4-thiouracil, 5-aminouracil, 5-(C₁-C₆)-alkyluracil, 5-(C₂-C₆)-alkenyluracil, 5-(C₂-C₆)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C₁-C₆)-alkylcytosine, 5-(C₂-C₆)-alkenylcytosine, 5-(C₂-C₆)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine,

- 19 -

5-bromocytosine, N²-dimethylguanosine, 2,4-diamino-purine, 8-azapurine, a substituted 7-deazapurine, preferably 7-deaza-7-substituted and/or 7-deaza-8-substituted purine or other modifications of a natural nucleoside bases. This list is meant to be exemplary and is not to be interpreted to be limiting.

The oligonucleotides of the present invention are nucleic acids that contain specific sequences found to elicit an immune response. These specific sequences that elicit an immune response are referred to as "immunostimulatory motifs", and the oligonucleotides that contain immunostimulatory motifs are referred to as "immunostimulatory nucleic acid molecules" and, equivalently, "immunostimulatory nucleic acids" or "immunostimulatory oligonucleotides". The immunostimulatory oligonucleotides of the invention thus include at least one immunostimulatory motif.

In one embodiment of the invention the immunostimulatory oligonucleotides include immunostimulatory motifs which are "CpG dinucleotides". A CpG dinucleotide can be methylated or unmethylated. An immunostimulatory nucleic acid containing at least one unmethylated CpG dinucleotide is a nucleic acid molecule which contains an unmethylated cytosine-guanine dinucleotide sequence (i.e., an unmethylated 5' cytosine followed by 3' guanosine and linked by a phosphate bond) and which activates the immune system; such an immunostimulatory nucleic acid is a CpG nucleic acid. CpG nucleic acids have been described in a number of issued patents, published patent applications, and other publications, including U.S. Patent Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068.

An immunostimulatory nucleic acid containing at least one methylated CpG dinucleotide is a nucleic acid which contains a methylated cytosine-guanine dinucleotide sequence (i.e., a methylated 5' cytosine followed by a 3' guanosine and linked by a phosphate bond) and which activates the immune system. In other embodiments the immunostimulatory oligonucleotides are free of CpG dinucleotides. These oligonucleotides which are free of CpG dinucleotides are referred to as non-CpG oligonucleotides, and they have non-CpG immunostimulatory motifs. The invention, therefore, also encompasses nucleic acids with other types of immunostimulatory motifs, which can be methylated or unmethylated. The immunostimulatory oligonucleotides of the invention, further, can include any combination of methylated and unmethylated CpG and non-CpG

- 20 -

immunostimulatory motifs. In some embodiments the immunostimulatory oligonucleotide is not an antisense oligonucleotide.

As used herein, a "Toll-like receptor (TLR) that signals in response to the CpG nucleic acid" refers to any TLR that engages or initiates an intracellular signaling pathway associated with the development of an immune response, as a result of contacting the TLR with CpG nucleic acid. The pathway typically involves the adaptor protein MyD88 and subsequent downstream molecules including TRAF, IRAK, Jun, Erk, p38 MAPK, and NF- κ B. The TLRs are a family of at least ten highly conserved receptors that share as a common feature a cytoplasmic Toll homology IL-1 receptor (TIR) domain believed to be involved in such signaling. TLR9 is reported to be the natural receptor for CpG nucleic acid.

As to CpG nucleic acids, it has recently been described that there are different classes of CpG nucleic acids. One class is potent for activating B cells but is relatively weak in inducing IFN- α and NK cell activation; this class has been termed the B class. The B class CpG nucleic acids typically are fully stabilized and include an unmethylated CpG dinucleotide within certain preferred base contexts. See, e.g., U.S. Patent Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068. Another class is potent for inducing IFN- α and NK cell activation but is relatively weak at stimulating B cells; this class has been termed the A class. The A class CpG nucleic acids typically have stabilized poly-G sequences at 5' and 3' ends and a palindromic phosphodiester CpG dinucleotide-containing sequence of at least 6 nucleotides. See, for example, published patent application PCT/US00/26527 (WO 01/22990). Yet another class of CpG nucleic acids activates B cells and NK cells and induces IFN- α ; this class has been termed the C class. The C class CpG nucleic acids typically are fully stabilized, include a B class-type sequence and a GC-rich palindrome or near-palindrome. This class has been described in published patent application PCT/US02/26468 (WO 03/015711), the entire content of which is incorporated herein by reference.

Immunostimulatory oligonucleotides are effective in vertebrates. Different immunostimulatory oligonucleotides can cause optimal immune stimulation depending on the type of subject and the sequence of the immunostimulatory oligonucleotide. Many vertebrates have been found according to the invention to be responsive to the same class of immunostimulatory oligonucleotides, sometimes referred to as human specific immunostimulatory oligonucleotides. Rodents, however, respond to different nucleic acids.

- 21 -

Immunostimulatory oligonucleotides causing optimal stimulation in humans may not generally cause optimal stimulation in a mouse and vice versa. An immunostimulatory oligonucleotide causing optimal stimulation in humans often does, however, cause optimal stimulation in other animals such as cow, horses, sheep, etc. For example, within Class B CpG ODN, preferred immunostimulatory sequences have been identified for use in mice (ODN 1826, 5'- TCCATGACGTTCTGACGTT -3', SEQ ID NO:18) and for use in humans (ODN 2006, 5'- TCGTCGTTTGTGCGTTTGTCGTT -3', SEQ ID NO:19). One of skill in the art can identify the optimal immunostimulatory nucleic acid sequences useful for a particular species of interest using routine assays described herein and/or known in the art, using the guidance supplied herein.

As used herein, the term "treat" as used in reference to a disease or condition shall mean to intervene in such disease or condition so as to prevent or slow the development of, slow the progression of, halt the progression of, or eliminate the disease or condition. Thus the phrase "to treat the prion disease" as used herein means to prevent or slow the development of, slow the progression of, halt the progression of, or eliminate the prion disease.

As used herein, a "subject" refers to a human or non-human vertebrate. Preferred non-human vertebrates include feed livestock susceptible to TSE, including cows and cattle, sheep, goats, and pigs. Non-human subjects also specifically include non-human primates as well as rodents. Non-human subjects also include, without limitation, chickens, horses, dogs, cats, guinea pigs, hamsters, mink, and rabbits.

As used herein, a "subject having a prion disease" is a subject known or diagnosed to have a prion disease as disclosed herein. Generally a subject having a prion disease will have some objective manifestation of the prion disease, such as a sign, symptom, or result of a suitable diagnostic test that indicates the presence of a prion disease. In the transmissible spongiform encephalopathies, such objective manifestations can include dementia, ataxia, myoclonus, tremor, presence of protease-resistant prion protein in brain extract, and typical or characteristic abnormalities on brain CT, brain MRI, and/or EEG. This list is not meant to be limiting in any way, and those of skill in the art will recognize what criteria are suitable for making a diagnosis of prion disease in a given species in question. A subject having a prion disease shall also include any subject having a test result which specifically indicates the presence in that subject of any amount of prion protein that is associated with a prion

- 22 -

disease, since it is believed that prion protein that is associated with a prion disease is not present in a subject without a prion disease.

A subject having a prion disease can but need not necessarily have an identifiable risk factor for having a prion disease. An identifiable risk factor for having a prion disease can include a family history of prion disease, a history of consuming known or suspected prion-diseased tissue, or a history of exposure to a prion protein that is associated with a prion disease or to a product derived from a known or suspected prion-diseased tissue (e.g., through administration of pituitary extract).

As used herein, a "subject at risk of developing a prion disease" is a subject with a known or suspected exposure to prion-diseased tissue, a known or suspected exposure to prion protein that is associated with a prion disease, or a known or suspected predisposition to develop a prion disease (e.g., family history of prion disease). In one embodiment the subject at risk of developing a prion disease is a subject residing in or traveling to an area in which TSE is endemic. In one embodiment the subject at risk of developing a prion disease is a subject residing in or traveling to an area in which food or water contains or is likely to contain prion protein that is associated with prion disease. In one embodiment, a subject at risk of developing a prion disease is a subject with a known or suspected iatrogenic exposure to prion-diseased tissue, e.g., neurosurgeons, neuropathologists, pathologists, nurses, morticians, histology technicians and laboratory workers at special risk of contracting iCJD. In one embodiment, a subject at risk of developing a prion disease is a subject with a known or suspected iatrogenic exposure to prion-diseased tissue through receiving a tissue or organ allograft from a subject having a prion disease. Such tissues can include, without limitation, corneas and dural grafts.

As used herein, an "effective amount" of a substance generally refers to that amount of the substance that is sufficient to bring about a desired effect. With reference to CpG nucleic acid, an "effective amount to induce an immune response to the prion protein" shall refer to that amount of CpG nucleic acid that is sufficient to induce an immune response to a particular prion protein. The immune response can occur in vitro, in vivo, ex vivo, and any combination thereof. An immune response to a prion protein can be measured using any suitable means to determine that an immune response occurs in association with exposure of an immune cell to the prion protein. The immune response can be antigen-specific, including any of the following: production of prion protein-specific antibody, proliferation of prion

- 23 -

protein-specific lymphocytes, and cell-mediated immunity against cells expressing prion protein. The immune response can alternatively or additionally be antigen-nonspecific, including any of the following: induction of a Toll-like receptor signaling pathway, inflammation, and production of a cytokine and/or chemokine. Because prion proteins are generally believed not to evoke an immune response, any prion protein-specific immune response which occurs in association with exposure of an immune cell to a prion protein will generally indicate an immune response to the prion protein.

Also with reference to CpG nucleic acid, an "effective amount to treat the prion disease" shall refer to that amount of CpG nucleic acid that is sufficient to treat a particular prion disease. In one embodiment, an effective amount to treat the prion disease is that amount that is sufficient to slow the development of prion disease, compared to the rate of development of prion disease that would occur without CpG administration according to the instant invention. In one embodiment, an effective amount to treat the prion disease is that amount that is sufficient to prevent the development of prion disease, compared to development of prion disease that would occur without CpG administration according to the instant invention. In one embodiment an effective amount to treat the prion disease is that amount that is sufficient to slow the progression of prion disease, compared to the rate of progression of prion disease that would occur without CpG administration according to the instant invention. In one embodiment an effective amount to treat the prion disease is that amount that is sufficient to stop the progression of prion disease, compared to the progression of prion disease that would occur without CpG administration according to the instant invention. In one embodiment an effective amount to treat the prion disease is that amount that is sufficient to resolve prion disease, compared to the prion disease that would occur without CpG administration according to the instant invention.

Combined with the teachings provided herein, by choosing among the various active compounds and weighing factors such as potency, relative bioavailability, patient body weight, severity of adverse side-effects and preferred mode of administration, an effective prophylactic or therapeutic treatment regimen can be planned which does not cause substantial toxicity and yet is entirely effective to treat the particular subject. The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular immunostimulatory oligonucleotide being administered, the antigen, the size of the subject, or the severity of the disease or condition.

- 24 -

One of ordinary skill in the art can empirically determine the effective amount of a particular immunostimulatory oligonucleotide and/or other therapeutic agent without necessitating undue experimentation.

Subject doses of the immunostimulatory oligonucleotides for mucosal or local delivery typically range from about 0.1 µg to 10 mg per administration, which depending on the application could be given daily, weekly, or monthly and any other amount of time therebetween. More typically doses range from about 10 µg to 5 mg per administration, and most typically from about 100 µg to 1 mg, with repeated administrations being spaced days or weeks apart. Subject doses of immunostimulatory oligonucleotides for parenteral delivery for the purpose of inducing an antigen-specific immune response, wherein the compounds are delivered with an antigen but not another therapeutic agent are typically 5 to 10,000 times higher than the effective mucosal dose for vaccine adjuvant or immune stimulant applications, and more typically 10 to 1,000 times higher, and most typically 20 to 100 times higher. Doses of the immunostimulatory oligonucleotides for parenteral delivery for the purpose of inducing an innate immune response or for inducing an antigen-specific immune response when the immunostimulatory nucleic acids are administered in combination with other therapeutic agents or in specialized delivery vehicles typically range from about 0.1 µg to 10 mg per administration, which depending on the application could be given daily, weekly, or monthly and any other amount of time therebetween. More typically parenteral doses for these purposes range from about 10 µg to 5 mg per administration, and most typically from about 100 µg to 1 mg, with repeated administrations being spaced days or weeks apart. In some embodiments, however, parenteral doses for these purposes may be used in a range of 5 to 10,000 times higher than the typical doses described above.

For any immunostimulatory oligonucleotide the therapeutically effective amount can be initially determined from animal models. A therapeutically effective dose can also be determined from human data for CpG oligonucleotides which have been tested in humans (human clinical trials have been initiated) and for compounds which are known to exhibit similar pharmacological activities, such as other mucosal adjuvants, e.g., LT and other antigens for vaccination purposes, for mucosal or local administration. Higher doses are required for parenteral administration. The applied dose can be adjusted based on the relative bioavailability and potency of the administered immunostimulatory oligonucleotide. Adjusting the dose to achieve maximal efficacy based on the methods described herein and

- 25 -

other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.

The immunostimulatory oligonucleotide can be administered alone or with antigen or other therapeutic agent. In this context, "antigen" refers to any biological molecule capable of eliciting specific immunity. Antigens specifically include peptides (oligopeptides, polypeptides, proteins, and glycosylated derivatives thereof), and polysaccharides. Peptide antigen can be administered preformed or as a polynucleotide encoding the peptide. Also in this context, "other therapeutic agent" includes any suitable composition useful in treating prion disease, including an antibody capable of binding a prion protein. When the immunostimulatory oligonucleotide is administered with antigen or other therapeutic agent, the immunostimulatory oligonucleotide can be administered before, concurrently with, or following administration of the antigen or other therapeutic agent. The immunostimulatory oligonucleotide and the antigen or other therapeutic agent can be formulated together or separately when the immunostimulatory oligonucleotide is administered concurrently with the antigen or other therapeutic agent. When the immunostimulatory oligonucleotide is administered before or following administration of antigen or other therapeutic agent, the immunostimulatory oligonucleotide and the antigen or other therapeutic agent can be administered by the same route of administration or by different routes of administration. In addition, when the immunostimulatory oligonucleotide is administered before or following administration of antigen or other therapeutic agent, the immunostimulatory oligonucleotide and the antigen or other therapeutic agent can be administered to the same site or to different sites.

The immunostimulatory oligonucleotides may be directly administered to the subject or may be administered in conjunction with a nucleic acid delivery complex. A nucleic acid delivery complex shall mean a nucleic acid molecule associated with (e.g., ionically or covalently bound to; or encapsulated within) a targeting means (e.g., a molecule that results in higher affinity binding to target cell (e.g., B cell surfaces and/or increased cellular uptake by target cells). Examples of nucleic acid delivery complexes include nucleic acids associated with a sterol (e.g., cholesterol), a lipid (e.g., a cationic lipid, virosome or liposome), or a target cell specific binding agent (e.g., a ligand recognized by target cell specific receptor). Preferred complexes may be sufficiently stable *in vivo* to prevent significant uncoupling prior to internalization by the target cell. However, the complex can

- 26 -

be cleavable under appropriate conditions within the cell so that the nucleic acid is released in a functional form.

Delivery vehicles or delivery devices for delivering antigen and nucleic acids to surfaces have been described. The immunostimulatory oligonucleotide and/or the antigen and/or other therapeutics may be administered alone (e.g., in saline or buffer) or using any delivery vehicles known in the art. For instance the following delivery vehicles have been described: cochleates (Gould-Fogerite et al., 1994, 1996); emulsomes (Vancott et al., 1998, Lowell et al., 1997); ISCOMs (Mowat et al., 1993, Carlsson et al., 1991, Hu et., 1998, Morein et al., 1999); liposomes (Childers et al., 1999, Michalek et al., 1989, 1992, de Haan 1995a, 1995b); live bacterial vectors (e.g., *Salmonella*, *Escherichia coli*, bacillus Calmette-Guérin, *Shigella*, *Lactobacillus*) (Hone et al., 1996, Pouwels et al., 1998, Chatfield et al., 1993, Stover et al., 1991, Nugent et al., 1998); live viral vectors (e.g., *Vaccinia*, adenovirus, Herpes Simplex) (Gallichan et al., 1993, 1995, Moss et al., 1996, Nugent et al., 1998, Flexner et al., 1988, Morrow et al., 1999); microspheres (Gupta et al., 1998, Jones et al., 1996, Maloy et al., 1994, Moore et al., 1995, O'Hagan et al., 1994, Eldridge et al., 1989); nucleic acid vaccines (Fynan et al., 1993, Kuklin et al., 1997, Sasaki et al., 1998, Okada et al., 1997, Ishii et al., 1997); polymers (e.g., carboxymethylcellulose, chitosan) (Hamajima et al., 1998, Jabbal-Gill et al., 1998); polymer rings (Wyatt et al., 1998); proteosomes (Vancott et al., 1998, Lowell et al., 1988, 1996, 1997); sodium fluoride (Hashi et al., 1998); transgenic plants (Tacket et al., 1998, Mason et al., 1998, Haq et al., 1995); virosomes (Gluck et al., 1992, Mengiardi et al., 1995, Cryz et al., 1998); virus-like particles (Jiang et al., 1999, Leibl et al., 1998).

The immunostimulatory oligonucleotides may be administered by any means known to the skilled artisan. Routes of administration include but are not limited to oral, mucosal, parenteral, intravenous, intramuscular, intraperitoneal, intranasal, intratracheal, sublingual, subcutaneous, intradermal, inhalation, ocular, vaginal, and rectal.

The immunostimulatory oligonucleotides are administered in pharmaceutically acceptable solutions, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.

Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated, coated onto microscopic

- 27 -

gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of methods for drug delivery, see Langer R (1990) *Science* 249:1527-33, which is incorporated herein by reference.

The immunostimulatory oligonucleotides and optionally other therapeutics and/or antigens may be administered *per se* (neat) or in the form of a pharmaceutically acceptable salt. When used in medicine the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof. Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic. Also, such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.

Suitable buffering agents include: acetic acid and a salt (1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v). Suitable preservatives include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).

For oral administration, the immunostimulatory oligonucleotides can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose,

- 28 -

mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers for neutralizing internal acid conditions or may be administered without any carriers.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

- 29 -

The immunostimulatory oligonucleotides, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active compounds may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The immunostimulatory oligonucleotides may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the immunostimulatory oligonucleotides may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

The term "pharmaceutically-acceptable carrier" means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration to a

- 30 -

human or other vertebrate animal. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being commingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficiency.

The immunostimulatory oligonucleotides useful in the invention may be delivered in mixtures with additional adjuvant(s), other therapeutics, or antigen(s). A mixture may consist of several adjuvants in addition to the immunostimulatory oligonucleotide or several antigens or other therapeutics.

The particular mode selected will depend, of course, upon the particular adjuvants or antigen selected, the particular condition being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of an immune response without causing clinically unacceptable adverse effects. Preferred modes of administration are discussed above.

The immunostimulatory oligonucleotides may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the immunostimulatory oligonucleotides into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product. Liquid dose units are vials or ampoules. Solid dose units are tablets, capsules and suppositories. For treatment of a patient, depending on activity of the compound, manner of administration, purpose of the immunization (i.e., prophylactic or therapeutic), nature and severity of the disorder, age and body weight of the patient, different doses may be necessary. The administration of a given dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units. Multiple administration of doses at specific intervals of weeks or months apart is usual for boosting the antigen-specific responses.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the compounds,

- 31 -

increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di-and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480, 5,133,974 and 5,407,686. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.

Examples

Example 1. CpG-ODN Protects Mice from Scrapie Prion.

Groups of 8 mice each were inoculated intraperitoneally with 100 µl of 10% brain homogenates from mice terminally ill with RML scrapie prion strain corresponding to an infectious challenge of approximately 10^4 LD₅₀. The mice received 0.15 pmol (30 µl of 5 nM solution) CpG-ODN (oligonucleotide 1826, 5'- TCCATGACGTTCTGACGTT -3', SEQ ID NO:18), which has been shown to be a strong inducer of innate immunity and to confer sterile immunity against certain infectious diseases. Sparwasser T et al. (2000) *Eur J Immunol* 30:3591-7. CpG-ODN was administered intraperitoneally at the time of inoculation (0h) with scrapie prions as well as 4 times at intervals of 24h (4 x q 24h); a second group received 0.15 pmol (30 µl of 5 nM solution) CpG-ODN 7h after infection (7h) and 4 times at intervals of 24h (4 x q 24h); a third group received CpG-ODN at 7h after infection and subsequently 20 times at intervals of 24h (20 x q 24h). Controls matched for age and sex were given saline instead of CpG-ODN at the identical time intervals. Additional control experiments were also performed in uninfected mice using saline and brain homogenates of

- 32 -

uninfected mice. All animals were observed and scored daily for clinical signs of disease. Scrapie in mice is characterized by ataxia of gait, tremor, difficulty righting from a supine position, and tail rigidity. Occurrence of two of these four symptoms was used as the end point criterion for establishing a clinical diagnosis of scrapie. Western blots of brain homogenates were performed to confirm the diagnosis. All results were analyzed using the Student's t test (Table 1).

Table 1. Mean incubation time in C57BL/6 mice after inoculation with scrapie strain RML and treatment with CpG-ODN.

Group	Inoculation	Treatment	Regimen	Time to Terminal Disease (d) ± SD	Attack Rate
1	RML	CpG 1826	0h and 4 x q 24h	253 ± 4	8/8
2	RML	CpG 1826	7h and 4 x q 24h	250 ± 6	8/8
3	RML	CpG 1826	7h and 20 x q 24h	> 330 no disease	0/8
4	RML	Saline	0h and 4 x q 24h	183 ± 7	8/8
5	RML	Saline	7h and 4 x q 24h	181 ± 3	8/8
6	RML	Saline	7h and 20 x q 24h	181 ± 3	8/8
7	Saline	CpG 1826	0h and 4 x q 24h	No disease	0/8
8	Saline	CpG 1826	7h and 4 x q 24h	No disease	0/8
9	Saline	CpG 1826	7h and 20 x q 24h	No disease	0/8
10	Brain homogenate of uninfected mouse	CpG 1826	0h and 4 x q 24h	No disease	0/8
11	Brain homogenate of uninfected mouse	CpG 1826	7h and 4 x q 24h	No disease	0/8
12	Brain homogenate of uninfected mouse	CpG 1826	7h and 20 x q 24h	No disease	0/8

Mice infected with the RML strain which received CpG-ODN at the time of inoculation and 7h post-infection as well as 4 times at intervals of 24h showed a dramatic prolongation of survival time compared to control mice with an increase in survival time of 38% in both cases. These differences were highly significant ($p < 0.0001$). The application of CpG-ODN 7h post-inoculation and 20 times at 24h intervals led to disease-free intervals of more than 330 days. All control groups which were not inoculated with the RML strain remained disease-free, and no harmful effect of CpG-ODN application was observed.

- 33 -

These results showed that the application of CpG-ODN at the time of infection and 7h after infection led to a dramatic prolongation of survival time. This effect can be amplified when CpG-ODN are given for a longer period of time. The application of CpG-ODN for 20 times at 24h intervals results in a disease-free interval of >330 days, which indicates the great potential of CpG-ODN for post-exposure prophylaxis of people with exposure to infection. The mechanism of disease prevention remains to be determined, but it seems that the most likely explanation for this effect is a stimulation of TLR-expressing cells of the innate immune system, e.g., macrophages, monocytes, and especially dendritic cells. Sparwasser T et al. (2000) *Eur J Immunol* 30:3591-7. CpG-ODN has been known to induce resistance against other infectious diseases. Zimmermann S et al. (1998) *J Immunol* 160:3627-30. The induction of extreme prolongation of the incubation time or even resistance to prion disease was a surprising finding in the context of a completely different infectious agent.

The findings presented here show that administration of CpG-ODN prolongs the incubation time by 38% and may have the potential to prevent infection after repeated administration, even when high doses of infectivity are administered intraperitoneally. It may therefore be possible to prevent disease after inadvertent iatrogenic exposure with much lower infectious doses administered peripherally.

Example 2. Effect of Timing Between Exposure to Prion and Administration of CpG-ODN.

Mice are injected with RML scrapie prion or control and treated with CpG-ODN or control essentially as in Example 1, except that the interval between injection with RML scrapie prion or control and administration of CpG-ODN or control is varied. In some groups administration of CpG-ODN is delayed as much as a month following injection with RML scrapie prion or control. In some groups administration of CpG-ODN precedes injection with RML scrapie prion or control. In some groups the number and schedule of repeated administrations of CpG-ODN is varied from Example 1. Results, measured as in Example 1, show that CpG-ODN is effective even when administered more than 7h after injection with RML scrapie prion.

Example 3. Mice Protected from Scrapie Prion by CpG-ODN Develop an Immune Response to Prion.

- 34 -

Mice are injected with RML scrapie prion or control and treated with CpG-ODN or control essentially as in Example 1 or Example 2. At various time points following injection with RML scrapie prion or control and treatment with CpG-ODN or control, tissue or blood samples are obtained and analyzed for prion-specific and prion-nonspecific immune response. Presence of an immune response is determined by suitable method or measurement including, without limitation, antibody titer, enzyme-linked immunosorbent assay (ELISA), flow cytometry, cell proliferation assay, cytotoxicity assay, polymerase chain reaction (PCR) and reverse transcriptase-polymerase chain reaction (RT-PCR), Western immunoblot, Northern blot, and Southern blot. General methods for these types of measurements are standard and are suitably adapted to the specific antigen or stimulus being assayed. For example, ELISA is used to measure production of various secreted products, including antibodies, cytokines and chemokines. Cytokines and chemokines in this example include interleukin (IL)-4, IL-10, IL-6, IL-12, IL-18, interferon (IFN)- α , IFN- β , IFN- γ , tumor necrosis factor (TNF), and IP-10. Flow cytometry is used to measure cell surface and intracellular proteins, including markers associated with immune cell activation. Markers associated with immune cell activation can vary with cell type but include cluster of differentiation (CD) markers such as CD86, major histocompatibility complex (MHC), inducible cytokine receptors, and certain costimulatory molecules. Results show that CpG-ODN induces an immune response to prion protein.

Example 4. Selection of CpG-ODN.

Mice are injected with RML scrapie prion or control and treated with CpG-ODN or control essentially as in Example 1 or Example 2. Various CpG-ODN are compared against ODN 1826 for their effectiveness. Results, measured as in Example 1, show that protection is related to the use of species-optimized CpG-ODN.

Example 5. Use of CpG-ODN in Alzheimer's Disease Model.

Mice genetically susceptible to developing Alzheimer's-like disease are administered CpG nucleic acid alone or CpG nucleic acid plus antigen (e.g., amyloid precursor protein or A β), either prior to or following onset of Alzheimer's-like disease. Similar mice are administered appropriate control treatment. Animals are monitored for behavioral and histologic evidence of Alzheimer's-like disease.

- 35 -

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

We claim:

- 36 -

Claims

1. A method for treating a prion disease in a subject, comprising:
administering to a subject having or at risk of developing a prion disease a CpG nucleic acid in an effective amount to treat the prion disease.
2. The method according to claim 1, wherein the administering follows exposure of the subject to a prion protein that is associated with a prion disease.
3. The method according to claim 1, wherein the prion disease is a transmissible spongiform encephalopathy (TSE).
4. The method according to claim 1, wherein the prion disease is scrapie.
5. The method according to claim 1, wherein the prion disease is bovine spongiform encephalopathy (BSE).
6. The method according to claim 1, wherein the prion disease is variant Creutzfeldt-Jakob disease (vCJD).
7. The method according to claim 1, wherein the prion disease is iatrogenic Creutzfeldt-Jakob disease (iCJD).
8. The method according to claim 1, wherein the subject is a human.
9. A method for inducing an immune response to a prion protein, comprising:
contacting an antigen-presenting cell (APC) with a prion protein; and
contacting the APC with a CpG nucleic acid in an effective amount to induce an immune response to the prion protein.
10. The method according to claim 9, wherein the immune response is in vivo.

- 37 -

11. The method according to claim 9, wherein the APC is selected from the group consisting of: a B cell, a dendritic cell, a macrophage, and a monocyte.
12. The method according to claim 9, wherein the APC is a dendritic cell.
13. The method according to claim 9, wherein the APC expresses a Toll-like receptor (TLR) that signals in response to the CpG nucleic acid.
14. The method according to claim 13, wherein the TLR is TLR9.
15. The method according to claim 9, wherein the prion protein is prion protein:scrapie form (PrP^{Sc}).
16. The method according to claim 9, wherein the prion protein is a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc} .
17. The method according to claim 9, wherein the prion protein is a derivative of PrP^{Sc} or a derivative of a fragment of PrP^{Sc} lacking at least the amino terminus of full-length PrP^{Sc} .
18. The method according to claim 9, wherein the CpG nucleic acid is a Class B CpG nucleic acid.
19. The method according to claim 9, wherein the CpG nucleic acid is a Class A CpG nucleic acid.
20. The method according to claim 9, wherein the CpG nucleic acid is a Class C CpG nucleic acid.
21. The method according to claim 9, wherein the CpG nucleic acid is optimized for use in a species of the subject.

SEQUENCE LISTING

<110> Coley Pharmaceutical GmbH
<120> USE OF CpG NUCLEIC ACIDS IN PRION DISEASE
<130> C01041.70038
<150> US 60/396,432
<151> 2002-07-17
<160> 19
<170> PatentIn version 3.1
<210> 1
<211> 2415
<212> DNA
<213> Homo sapiens

<400> 1
cggcgccgcg agcttctcct ctcctcacga ccgaggcaga gcagtcatta tggcgaacct 60
tggctgctgg atgctggttc tctttgtggc cacatggagt gacctgggcc tctgcaagaa 120
.gcgcggcaag cctggaggat ggaacactgg gggcagccga tacccggggc agggcagccc 180
tggaggcaac cgctaccac ctcagggcgg tggtggtgg gggcagcctc atggtggtgg 240
ctggggcag cctcatggtg gtggctgggg gcagccccat ggtggtgtggct ggggacagcc 300
tcatgggtt ggctggggtc aaggaggtgg cacccacagt cagtggaaaca agccgagtaa 360
gcacaaaaacc aacatgaagc acatggctgg tgctcagca gctggggcag tggtgggggg 420
ccttggcggc tacatgctgg gaagtgcatt gagcaggccc atcatacatt tcggcagtga 480
ctatgaggac cgttactatc gtgaaaacat gcaccgttac cccaaccaag tgtactacag 540
gcacatggat gagtacagca accagaacaa ctttgcac gactgcgtca atatcacaat 600
caaggcagcac acggtcacca caaccaccaa gggggagaac ttccaccgaga ccgacgttaa 660
gatgatggag cgcgtgggtt agcagatgtg tatcaccag tacgagaggg aatctcaggc 720
ctattaccag agaggatcga gcatggtcct cttctcctt ccacctgtga tcctcctgat 780
ctcttccttc atcttcctga tagtgggatg aggaaggctt tcctgtttt accatcttc 840
taatctttt ccagtttag ggaggcggta tccacctgca gcccttttag tggtggtgtc 900
tcactcttc ttctctctt gtcccgata ggctaataa tacccttggc actgatggc 960
actggaaaac atagagtaga cctgagatgc tggtaagcc ccctttgatt gagttcatca 1020
tgagccgtt ctaatgccag gccagtaaaa gtataacagc aaataaccat tggtaatct 1080
ggacttattt ttggacttag tgcaacaggt tgaggctaaa acaaatctca gaacagtctg 1140

aaatacctt gcctggatac ctctggctcc ttcagcagct agagctcagt atactaatgc 1200
 cctatcttag tagagatttc atagctattt agagatattt tccattttaa gaaaaccgaa 1260
 caacatttct gccagggttg ttaggaggcc acatgatact tattcaaaaa aatcctagag 1320
 attcttagct cttgggatgc aggctcagcc cgctggagca tgagctctgt gtgtaccgag 1380
 aactgggtg atgtttact tttcacagta tgggctacac agcagctgtt caacaagagt 1440
 aaatattgtc acaacactga acctctggct agaggacata ttcacagtga acataactgt 1500
 aacatatatg aaaggcttct gggacttgaa atcaaatgtt tggaaatgggt gcccctggag 1560
 gcaacacctcc attttagatg tttaaaggac cctatatgtg gcattccctt ctttaaacta 1620
 tagtaatta aggcagctga aaagtaaatt gccttctaga cactgaaggc aaatctcctt 1680
 tgtccattta cctggaaacc agaatgattt tgacatacag gagagctgca gttgtgaaag 1740
 caccatcatc atagaggatg atgtaattaa aaaatggtca gtgtgcaaag aaaagaactg 1800
 cttgcatttc tttatttctg tctcataatt gtcaaaaacc agaatttaggt caagttcata 1860
 gtttctgtaa ttggcttttg aatcaaagaa tagggagaca atctaaaaaa tatcttaggt 1920
 tggagatgac agaaatatga ttgatttgaa gtggaaaaag aaattctgtt aatgttaatt 1980
 aaagtaaat tattccctga attgtttgat attgtcacct agcagatatg tattactttt 2040
 ctgcaatgtt attattggct tgcactttgt gагtатctat gtaaaaatat atatgtatat 2100
 aaaatataa ttgcatagga cagacttagg agtttggttt agagcagttt acatctgaag 2160
 tgtctaattgc attaactttt gtaaggtaact gaatacttaa tatgtggaa accctttgc 2220
 gtggtcctta ggcttacaat gtgcactgaa tcgtttcatg taagaatcca aagtggacac 2280
 cattaacagg tcttgaaat atgcatgtac tttatatttt ctatatttgt aactttgcat 2340
 gttcttgttt tgttatataa aaaaattgtt aatgttaat atctgactga aattaaacga 2400
 gcgaagatga gcacc 2415

<210> 2
 <211> 2446
 <212> DNA
 <213> Mustela sp.

<400> 2
 tcattttgtt ttgtttgtt ttgtttgcag ataagccatc atggtaaaaa gccacatagg 60
 cagctggctc ctggttctt ttgtggccac atggagtgac attggcttct gcaagaagcg 120
 gccaaagcct ggaggaggct ggaacactgg ggggagccga tacccagggc agggcagtcc 180
 tggaggcaac cgctacccac cccagggtgg tggcggctgg ggccagcccc acgggggtgg 240

ctggggacag ccccacgggg gtggctgggg tcagccccac gggggtggct gggacagcc	300
gcatggtggc ggtggctggg gtcaagggtgg tgggagccac ggtcagtggg gcaagcccag	360
taagccaaa accaacatga agcatgtggc gggagccgca gcagccgggg cggtcggtgg	420
gggcctgggc ggctacatgc tgggagcgc catgagcagg cccctcattc attttggcaa	480
cgactatgag gaccgctact accgtgagaa catgtaccgc taccccaacc aagtgtacta	540
caagccggtg gatcagtaca gcaaccagaa caacttcgtg catgactgcg tcaacatcac	600
ggtcaagcag cacacggtga ccaccaccac caagggcgag aacttcacgg agaccgacat	660
gaagatcatg gagcgcgtgg tggagcagat gtgtgtcacc cagtaccagc gagagtccga	720
ggcttactac cagagggggg cgagcgccat cctcttcgt cccctcccg tgatcctcct	780
catctcactg ctcattctcc tgatagtggg atgaggatgg cttccatt ctctccatcg	840
tcttcacctt ttacaggttg gggaggggg tgtctaccta cagccctgta gtggtgtgt	900
ctcattcctg cttctctta tcacccatag gctaatcccc ttggccctga tggccctggg	960
aaatgttagag cagacccagg atgctattta ttcaagcccc catgtgttgg agtccttcag	1020
gggccaatgc tagtgcaggg ctgagaataa cagcaaatca tcattggttg acctaggct	1080
gttttttgt tggttgttc tagtgcagct gaccgaggct aaaacaattc tcaaaacagt	1140
tttcaaatac cttgcctgg aaacctctgg ctcctgctgc agctagagct cagtagatta	1200
atgtcccatc ttagccgtgt cttcatagca acttggggaa gttttctcc ccactctaaa	1260
agaacgcgt tgcaattccc tgtgcaaaga acatttctgc caaatttggaa aggaggccac	1320
atgatattca ttcaaaaagc aaaactagaa accctttgct cttggacgca agcccgccct	1380
gctaggagca ccaaactggg gcgatggttt gcattctgctg gcgtgggcta tgcggcagcc	1440
gaggtgtcca gcgtaaatat tgatgcgacg ctagacctag gcagaggatg tttgcacagg	1500
gaatgaacat aatcaacagt gcgaaaatgc tacaaaaat cccacactgg ggagcagtgt	1560
ccttggaggc aagttttt cttttggga cattaaagc ccctatatgt ggcattcctt	1620
tcttcgtaa cctaaactat agataattaa ggcagttaaa aattgaactt cttccaggc	1680
cccaagagca aatctttgtt cacttacctg gaaaccagaa tgattttgac acagaggaag	1740
gtgcagctgt taaaataacc ctcatcctag aagatgcacatggagaaaa acgatccgta	1800
gacaaaaatg atcgcatttc ttcattgctg ttcgtattt gacagaaacc agaattatgt	1860
caagtcctag tttctataat cagttttga atcaaagaat ggaagtccat ccaaaaaaaaaa	1920
aaaagaaata ctttaggtca cccatgacag aaatacccat tcaggttaga aaaaaggaat	1980
tctgttaact gttatTTAAG taaggcaaaa ttattgtccg gattgttcga tatcatcagc	2040

tagcagataa attagcattc tgcaatgttc ccggcttgca ctgtgcgggt atttgatgtt 2100
 aaaaaaaaaatt attatatata ttgtgtatga caaacttaga agttttgct agaggagtt 2160
 acatctgata tatctaattgc accaccagtt ttggaaggta ctaaatactt aatatgtaga 2220
 aatccctttg cgtggtcctc aggcttacac gtgcactgaa tagtttgtt tggatagagcc 2280
 catgtggtct tcgaaatatg catgtacttt atatttcta tatttgaac tggcatgtt 2340
 cttgtataaa aaatgtataa acattcgaac tcttgacttag aatcaaacag gaactgagt 2400
 tgtcccatgt gtttgcagtg acattcacca ccgcaccctg ttttgg 2446

<210> 3
 <211> 810
 <212> DNA
 <213> Mesocricetus auratus

<400> 3
 tcgaaaatct cccttttag caatttcttg ctccataggt ttcagcaatt gctttctcg 60
 tccatttaggc aacccatcat tttctcacct tccccattat gtaacgggag caatgggttc 120
 tggaccagtc ttccattaaa gatgatttt atagtcggtg agcgccgtca gggagtgtatg 180
 acacctgggg gcggttaaa ccgtacaatc ccttaaacca gtctggagcg gtgactcatt 240
 tccccagggg gaagtggcgc ggccattggg gggcggcggc caagccccgc cccacccagc 300
 cccggccccgc cctgtatccc ctccctgactc actgccccgc ccgtcccccc gggcggtcc 360
 agcagcagac cgagaaggca catcgagtcc actcgatcg tcgggtggcag gtaagcggt 420
 tctgaaggct ggccccggg agggtgctgg agccaggcct cggtaaaggct tcggcttccc 480
 agagccaagc ccggcttact ccggctctcg gggcgctgag gccgcggggc tgagggttag 540
 tctggctggg aggtgaccgc gcacccgcag ccgcgcgtct ctttggggg ccgaacccca 600
 ggagaggcca ggagccatcc cttccctcccg agccggctc acccccagag tggatcggtt 660
 atggggatgt gggatgggg tggatcttt tgactgttgtt ttgtgtttt cttctcttt 720
 tgtaatagct acagcgaaca taatttacc cagggttcca ccgtggtctc gtccgtcctc 780
 ggcacatctc agtccagtagc atacccaagg 810

<210> 4
 <211> 4020
 <212> DNA
 <213> Ovis aries

<400> 4
 atggtaaaaa gccacatagg cagttggatc ctgggtctct ttgtggccat gtggagtgac 60

gtgggcctct gcaagaagcg accaaaacct ggccggaggat ggaacactgg ggggagccga	120
tacccgggac agggcagtcc tggaggcaac cgctatccac ctcagggagg gggtggctgg	180
ggtcagcccc atggaggtgg ctggggccaa cctcatggag gtggctgggg tcagccccat	240
ggtgtggct gggcacagcc acatggtggt ggaggctggg gtcaagggtgg tagccacagt	300
cagtggaaaca agccagtaa gccaaaaacc aacatgaagc atgtggcagg agctgctgca	360
gctggagcag tggtaggggg ctttggtggc tacatgctgg gaagtgccat gagcaggcct	420
cttatacatt ttggcaatga ctatgaggac cgttactatc gtgaaaacat gtaccgttac	480
cccaaccaag tgtactacag accagtggat cagtatagta accagaacaa ctttgtcat	540
gactgtgtca acatcacagt caagcaacac acagtcacca ccaccaccaa gggggagaac	600
ttcaccgaaa ctgacatcaa gataatggag cgagtggtgg agcaaatgtg catcacccag	660
taccagagag aatcccaggc ttattaccaa aggggggcaa gtgtgatcct cttttttcc	720
cctcctgtga tcctcctcat ctcttcctc atttttctca tagtaggata ggggcaacct	780
tcctgttttc attatcttct taatcttgc caggtgggg gagggagtgt ctacctgcag	840
ccctgttagtg gtgggtctc atttcttgct tctctttgt tacctgtata ataataccct	900
tggcgcttac agcaactggga aatgacaagc agacatgaga tgctgtttat tcaagtcacca	960
ttagctcagt attctaattgt cccatcttag cagtatttt gtagcaattt tctcatttg	1020
ttcaagaaca cctgactaca tttccctttg ggaatagcat ttctgccaag tctggaagga	1080
ggccacataa tattcattca aaaaaacaaa actggaaatc cttagttcat agaccagg	1140
tccaccctgt tgagagcatg tgcctgtgt ctgcagagaa ctataaagga tattctgcat	1200
tttgcagggtt acatttgcag gtaacacagc catctattgc atcaagaatg gatattcatg	1260
caaccttga ctatggca gaggacatct tcacaaggaa tgaacataat acaaaggctt	1320
ctgagactaa aaaattccaa catatggaaag aggtgccctt ggtggcagcc ttccattttg	1380
tatgtttaaag caccttcaag tgatattcct ttcttagta acataaagta tagataatta	1440
aggtaccta attaaactac cttctagaca ctgagagcaa atctgttgg tatctggaac	1500
ccaggatgtat ttgacatttgc ctttagggatg tgagagttgg actgtaaaga aagctgagtg	1560
ctgaagagtt catgcttttgc aactatagtg ttggagaaaa ctcttgagag tcccttgac	1620
tgaaaggaga tcagtcctga atattcatttgc gaaggactga tgctgaagct gaaactccaa	1680
tactttggtc acctgtatggg aagaactgaa ggcaggaggg atgcttaggaa agactgaagg	1740
caggaggaga agggacgac agaggatgag atggctagat ggcatcatgg actcaatggaa	1800
catgagctta agtaaactcc aggagttggc aatggacagg gagacctggc gtctgcagt	1860

ccatggtgtc gcagagtcgg acacgattga gtgactaaat tgaggtgacc cagatttaac	1920
atagagaatg cagatacaaaa actcatattc atttgattga atctttcct gaaccagtgc	1980
tagtgttggc ctggtaaggg tataacagca tatataggtt atgtgatgaa gagatagtgt	2040
acatgaaata tgtgcatttc ttattgctg tcattataatt gtcaaaaaaag aaaatttagt	2100
ccttggtttc tgtaaaaattt acttgaatca aaaggaggc atttaaagaa ataaattaga	2160
gatgatagaa atctgatcca ttcagagtag aaaaagaaat tccattactg ttattaaaga	2220
aggtaaaattt attccctgaa ttgttcaata ttgtcaccta gcagatagac actattctgt	2280
actgtttta ctagcttgca ccttggta tcctatgtaa aaacatattt gcatatgaca	2340
aacttttct gtttagagcaa ttaacatctg aaccacctaa tgcatcacct gttttgtaa	2400
ggtactttt gtaaggtact aaggagatgt gggttaatc cctaggcag gtaaaatcccc	2460
tagaggaaga aatggcaacc cactccagta ttcttgcag gaaaatccag tgggcagagg	2520
agcctggcag ggtacagtct aagagcatgg gggtgcaaag agtgagacaa gacttgagct	2580
actgaacaat aaggacaata aatgctgggt cggctaaaag gttcatttagg tttttttct	2640
gtaagatggc tctagtagta cttgtttta tcatttcattcg aaacaatttt gtttagattgt	2700
atgtgacagc tcttgttatca gcatgcattt gaaaaaaaaaca tcacaattgg taaatttttgc	2760
tatagccatc ttactattga agatggaaga aaagaagcaa aatttcagc atatcatgct	2820
gtacttattt caagaaagat aaccaaaaatg caaaaatgtt tttgtgaagt gtatggagaa	2880
ggggctgcaa ctgatcaagc ttgtcaaagt agtttgaa gtttcgtcgtc ggagatttct	2940
tattggacga tgctccacag ttggatatac cagttgaagt tgatagtgtt gaaatttgc	3000
tattgagaat aatcgatgtt ataccacgcg ggagatagct gacatactca aaatatccaa	3060
atagaacctt gaaaaccatt tgcaccatct cagttatgtt aatcactttt atgtttgagt	3120
tccacataag caaaaaaaaaaca acaacaaaaaaa aaaatacaac cttgaccata tttgcgcatt	3180
cagttctcta ctgaaatgtat tgaaaacact ttgttttaa aaacagattt tgattaacag	3240
tgggtacgt acaataacgt agatggaaga aattgttaggg tgagcaaat gaaccacacc	3300
acccaaaggcc agtcttcctc taaagaagat gtgtgtatgg tgggatttggaa aagtaatcct	3360
ctattatggc ttcttctggc aaacactgct cctaatttgc ccaactgaaa acagcactca	3420
acgaaaagca tccagaattt gtcaatagaa aacataatct tccatcaggaa taacgcaga	3480
ctacatattt ctttgatgac ccagcatggc tggagttct gattcatctg ttgtattcag	3540
acgttgcattc tttggatttt ttccattttat ttcagtcac aaaattatca taatggaaaa	3600

aatttccatt ccctggaaga tgtaaagtgc atctggaaaa ttctttgtc caaaaagata 3660
 aaaagtttg tgaacacaga attatgacgt tgcctgaaaa atggcagaag gtatgttgc 3720
 aaaagagtga ctatgttgc ttgtttaagg cttatgttgc aatggaaaaatgt tgtctttat 3780
 ttttatttaa acaccaaagg cacatggat caaccaata ctgaatctaa aggaaactct 3840
 tctgtgttgc gtccttacag tgcactga tagttgtat aagaatccag agtgcatttt 3900
 gaaatacgca tgcgttata tttttatat ttgtacttt gcatgtactt gttttgttgc 3960
 aaaagtttat aaatatttaa tatctgacta aaattaaaca ggagctaaaa ggagtatctt 4020

<210> 5
<211> 795
<212> DNA
<213> Bos taurus

<400> 5
 atggtaaaaa gccacatagg cagttggatc ctggttctct ttgtggccat gtggagtgac 60
 gtgggcctct gcaagaagcg accaaaacctt ggaggaggat ggaacactgg ggggagccga 120
 tacccaggac agggcagtcc tggaggcaac cgttatccac ctcaggagg gggtggctgg 180
 ggtcagcccc atggaggtgg ctggggccag cctcatggag gtggctgggg ccagcctcat 240
 ggaggtggct ggggtcagcc ccatggtggt ggctggggac agccacatgg tgggtggaggc 300
 tggggtcaag gtggtaccca cggtaatgg aacaaaccca gtaagccaaa aaccaacatg 360
 aagcatgtgg caggagctgc tgcagctgga gcagtggttag ggggccttgg tggctacatg 420
 ctgggaagtgc ccatgagcag gcctttata catggca gtgactatga ggaccgttac 480
 tatcgtgaaa acatgcaccg ttaccccaac caagtgtact acaggccagt ggatcgttat 540
 agtaaccaga acaactttgt gcatgactgt gtcaacatca cagtcaagga acacacagtc 600
 accaccacca ccaaggggga gaacttcacc gaaactgaca tcaagatgtt ggagcgagt 660
 gtggagcaaa tgcattttcc ccaatggatc agagaatccc aggcttatta ccaacgaggg 720
 gcaagtgtga tcctttctc ttcccttcctt gtgatcctcc tcattttttt ctcattttt 780
 ctcatagtag gatag 795

<210> 6
<211> 2188
<212> DNA
<213> Gallus gallus

<400> 6
 gaattccctc ggcagccagc tcctccctct cgctatggat ttctttctcc ccccccctacg 60
 ctggatctgg atcatctcaa gcccggatcggt gacggcttct tggatcgctc atacataaat 120

atctgtgagt cagaggaagc aaccacccgac cccaagaccc taccccgagc catggctagg	180
ctcctcacca cctgctgcct gctggccctg ctgctcgccg cctgcaccga cgtcgccctc	240
tccaaagaagg gcaaaggcaa acccagtggt gggggttggg gcgcggggag ccatcgccag	300
cccagctacc cccgccagcc gggctaccct cataacccag ggtaccccca taacccaggg	360
taccccaaca accctggcta tccccataac cccggctacc cccagaaccc tggctacccc	420
cataacccag gttacccagg ctggggtcaa ggctacaacc catccagcgg aggaagttac	480
cacaaccaga agccatggaa accccccaaa accaacttca agcacgtggc gggggcagca	540
gcggcgggtg ctgtgggtggg gggcttgggg ggctacgcca tggggcgcgt tatgtcaggg	600
atgaactacc acttcgatag acccgatgag taccgatggg ggagtgagaa ctcggcgcgt	660
tatcccaacc gggtttacta ccgggattac agcagccccg tgccacagga cgtcttcgtg	720
gcggattgt ttaacatcac agtgaactgag tacagcattg gccctgctgc caagaagaac	780
acctccgagg ctgtggcggc agcaaaccaa acggaggtgg agatggagaa caaagtggtg	840
acgaagggtga tccgcgagat gtgcgtgcag cagtaccgcg agtaccgcct ggcctcggc	900
atccagctgc accctgctga cacctggctc gccgtctcc tccctctctt caccaccctt	960
tttgcatgc actgatggga tgccgtgccc cggccctgtg gcagtgagat gacatcgtt	1020
ccccgtgccc acccatgggg tgttccttgt cctcgctttt gtccatcttt ggtgaagatg	1080
tccccccgt gcctccccgc aggctctgat ttgggcaaat gggagggat tttgtcctgt	1140
cctggtcgtg gcaggacggc tgctggtggt ggagtggat gcccaaaaaaaa tggccttcac	1200
cacttcctcc tcctcttcct ttctggggcg gagatatggg ctcgtccagc ccttattgtc	1260
cctgcaagag cgtatctgaa aatcctcttt gctaacaagc agggttttac ctaatctgct	1320
tagccccagt gacagcagag cgcctttccc cagggcacac caaccccaag ctgaggtgt	1380
tggcagccac acgtcccattt gaggctgatg ggttttgggg cgtcccaagc aacaccctgg	1440
gctactgagg tgcaattgta gctctttaat ctgccaatcc caaccctacc gtgttagatag	1500
gaactgcctg ctctgcattt tgcatgctgc aaacacccctcc tgccgcagcg cccccaaaaat	1560
agagtgattt gggaaatagtg aggctgaagc cacagcagct tgggattggg ctcatcatat	1620
caatccatga tgctttgctt ccagctgagc ctcactgccc ttttatagcc tgcccagagg	1680
aaggggagcgc tgctaaatgc cccaaaaaggt aacactgagc aaaagcttat ttcaatgtat	1740
gatagagaac gagtgcatct cgcacagatc agccatggga gcatcgtttgc ccatcagccc	1800
ccaaaacccaa aggatgctaa aatgcagccaa aaggggaaatc aagcacgcag ggaaggactt	1860

<210> 7
<211> 2097
<212> DNA
<213> *Mus musculus*

<400> 7
aattccttca gaactgaacc atttcaaccg agctgaagca ttctgccttc ctagtggtac 60
cagtccaatt taggagagcc aagcagacta tcagtcatca tggcgaacct tggctactgg 120
ctgctggccc tctttgtgac tatgtggact gatgtcgcc tctgcaaaaa gcggccaaag 180
cctggagggt ggaacaccgg tggaagccgg tatccccggc agggaaagccc tggaggcaac 240
cgttaccac ctcagggtgg cacctggggg cagccccacg gtggtggctg gggacaaccc 300
catggggca gctggggaca acctcatggt ggtagttggg gtcagccccca tggcggtgga 360
tggggccaag gagggggta ccataatcag tggaacaagc ccagcaaacc aaaaaccaac 420
ctcaagcatg tggcaggggc tgcggcagct ggggcagtag tggggggcct tgggtggctac 480
atgctgggga gcgccgtgag caggcccatg atccattttgc aacacgactg ggaggaccgc 540
tactaccgtg aaaaacatgta ccgctaccct aaccaagtgt actacaggcc agtggatcag 600
tacagcaacc agaacaactt cgtgcacgac tgcgtcaata tcaccatcaa gcagcacacg 660
gtcaccacca ccaccaaggg ggagaacttc accgagaccc atgtgaagat gatggagcgc 720
gtggtggagc agatgtgcgt caccctgtc cagaaggagt cccaggccta ttacgacggg 780
agaagatcca gcagcacccgt gctttctcc tcccctcctg tcatcctcct catctccttc 840
ctcatcttcc tgatcgtggg atgagggagg ctttcctgtc tggcccttc cattctcgtg 900
gtctaggctg ggggagggggt tatccacccgt tagctcttc aattgaggtg gttctcattc 960
ttgcttcctt ctgtccccca taggctaata cccctggcac tggatggccc tggaaatgt 1020
acagtagacc agttgtctt tgcttcaggt ccctttgtatc gaggctgtca tcagccagtg 1080
ctaacaccgg gccaataaga atataacacc aaataactgc tggctagttg gggctttgtt 1140
ttggtctagt gaataaatac tggtgtatcc cctgacttgt accccagagta caaggtgaca 1200

gtgacacatg taaccttagca taggcaaagg gttctacaac caaagaagcc actgtttggg	1260
gatggcgccc tggaaaacag cctcccacct gggatagcta gagcatccac acgtggaatt	1320
ctttcttac taacaaacga tagctgattg aaggcaacaa aaaaaaaaaa atcaaattgt	1380
cctactgacg ttgaaagcaa acctttgttc attcccaggc cactagaatg atctttagcc	1440
ttgcttgat tgaacttagga gatcttgact ctgaggagag ccagccctgt aaaaagcttg	1500
gtcctcctgt gacgggaggg atggtaagg tacaaaggct agaaacttga gtttcttcat	1560
ttctgtctca caattatcaa aagctagaat tagcttctgc cctatgttgc tgtacttcta	1620
tttgaactgg ataacagaga gacaatctaa acattctctt aggctgcaga taagagaagt	1680
aggctccatt ccaaagtggg aaagaaattc tgcttagcatt gtttaaatca ggccaaattt	1740
gttcctgaag ttgctttta ccccagcaga cataaaactgc gatagttca gcttgactg	1800
tggattttct gtatagaata tataaaacat aacttcaagc ttatgttcc tttttaaac	1860
atctgaagta tgggacgccc tggccgttcc atccagtact aaatgcttac cgtgtgaccc	1920
ttgggcttcc agcgtgcaact cagttccgtt ggattccaaa gcagaccctt agctggctt	1980
tgaatctgca tgtacttcac gttttctata tttgttaactt tgcatgttatt ttgtttgtc	2040
atataaaaag tttataaaatg tttgctatca gactgacatt aaatagaagc tatgatg	2097

<210> 8
 <211> 803
 <212> DNA
 <213> Ovis aries

<400> 8	
gcagagaagt catcatggtg aaaagccaca taggcagttg gatcctgggtt ctctttgtgg	60
ccatgtggag tgacgtgggc ctctgcaaga agcgacccaaa acctggcgga ggatggaaca	120
ctggggggag ccgatacccg ggacagggca gtcctggagg caaccgctat ccacctcagg	180
gaggggggtgg ctggggtcag cccatggag gtggctgggg ccaacctcat ggaggtggct	240
ggggtcagcc ccatggtgtt ggctggggac agccacatgg tggtgaggc tgggtcaag	300
gtggtagcca cagtcagtgg aacaagccca gtaagccaaa aaccaacatg aagcatgtgg	360
caggagctgc tgcaagctgga gcagtggtag ggggccttgg tggctacatg ctgggaagtg	420
ccatgagcag gcctttata cattttggca atgactatga ggaccgttac tatcgtgaaa	480
acatgtaccg ttaccccaac caagtgtact acagaccagt ggatcagtat agtaaccaga	540
acaactttgt gcatgactgt gtcaacatca cagtcaagca acacacagtc accaccacca	600
ccaaaggggga gaacttcacc gaaaactgaca tcaagataat ggagcgagtg gtggagccaa	660

tgtgcatacc	ccagtaccag	agagaatccc	aggcttatta	ccaaaggggg	gcaagtgtga	720
tcctctttc	ttccccctcc	gtgatcctcc	tcatctctt	cctcatttt	ctcatagtag	780
gataggggca	accccttgt	ttt				803

<210> 9
<211> 765
<212> DNA
<213> *Rattus norvegicus*

<400> 9						
atggcgaacc	ttggctactg	gctgctggcc	ctctttgtga	ctacatgtac	tgatgttggc	60
ctctgcaaaa	agcggccaaa	gcctggaggg	tggaacactg	gtggaagccg	gtaccctggg	120
cagggaaagcc	ctggaggcaa	ccgttaccca	cctcagagtg	gtggcacctg	ggggcagccc	180
catggtggtg	gctggggaca	acctcatggt	ggtggctggg	gacaacctca	tggtggtggc	240
tggggtcagc	cccatggcg	gggctggagt	caaggagggg	gtacccataa	tcagtggaac	300
aagcccagca	agccaaaaac	caacctaag	catgtggcag	gggctgccgc	agctggggca	360
gtagtggggg	gccttggtgg	ctacatgtt	gggagtgcca	tgagcaggcc	catgctccat	420
tttggcaacg	actgggagga	ccgctactac	cgagaaaaaca	tgtaccgtta	ccctaaccaa	480
gtgtactaca	ggccgggtgg	tcagtagcgc	aaccagaaca	acttcgtgca	cgactgtgtc	540
aatatcacca	tcaagcagca	tacagtcacc	accaccacca	agggggagaa	cttcacggag	600
accgacgtga	agatgatgga	gcgtgtggt	gagcagatgt	gcgtcacccca	gtatcagaag	660
gagtcccagg	cctattacga	cgggagaaga	tctagcgccg	tgctttctc	ctccccctcc	720
gtgatccotcc	tcatctcctt	cctcatcttc	ctgatcggtgg	gatga		765

<210> 10
<211> 253
<212> PRT
<213> *Homo sapiens*

<400> 10

Met	Ala	Asn	Leu	Gly	Cys	Trp	Met	Leu	Val	Leu	Phe	Val	Ala	Thr	Trp
1					5				10				15		

Ser	Asp	Leu	Gly	Leu	Cys	Lys	Lys	Arg	Pro	Lys	Pro	Gly	Gly	Trp	Asn
								25				30			
20															

Thr	Gly	Gly	Ser	Arg	Tyr	Pro	Gly	Gln	Gly	Ser	Pro	Gly	Gly	Asn	Arg
35						40						45			

Tyr Pro Pro Gln Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly
 50 55 60

Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly
 65 70 75 80

Trp Gly Gln Pro His Gly Gly Trp Gly Gln Gly Gly Thr His
 85 90 95

Ser Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn Met Lys His Met
 100 105 110

Ala Gly Ala Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly Gly Tyr
 115 120 125

Met Leu Gly Ser Ala Met Ser Arg Pro Ile Ile His Phe Gly Ser Asp
 130 135 140

Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn Met His Arg Tyr Pro Asn Gln
 145 150 155 160

Val Tyr Tyr Arg Pro Met Asp Glu Tyr Ser Asn Gln Asn Asn Phe Val
 165 170 175

His Asp Cys Val Asn Ile Thr Ile Lys Gln His Thr Val Thr Thr Thr
 180 185 190

Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp Val Lys Met Met Glu Arg
 195 200 205

Val Val Glu Gln Met Cys Ile Thr Gln Tyr Glu Arg Glu Ser Gln Ala
 210 215 220

Tyr Tyr Gln Arg Gly Ser Ser Met Val Leu Phe Ser Ser Pro Pro Val
 225 230 235 240

Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly
 245 250

<210> 11
 <211> 263
 <212> PRT
 <213> Bos taurus

<400> 11

Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val Ala
1 5 10 15

Met Trp Ser Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly
20 25 30

Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly
35 40 45

Asn Arg Tyr Pro Pro Gln Gly Gly Gly Trp Gly Gln Pro His Gly
50 55 60

Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His Gly
65 70 75 80

Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His Gly
85 90 95

Gly Gly Gly Trp Gly Gln Gly Gly Thr His Gly Gln Trp Asn Lys Pro
100 105 110

Ser Lys Pro Lys Thr Asn Met Lys His Val Ala Gly Ala Ala Ala Ala
115 120 125

Gly Ala Val Val Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala Met
130 135 140

Ser Arg Pro Leu Ile His Phe Gly Ser Asp Tyr Glu Asp Arg Tyr Tyr
145 150 155 160

Arg Glu Asn Met His Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Val
165 170 175

Asp Gln Tyr Ser Asn Gln Asn Asn Phe Val His Asp Cys Val Asn Ile
180 185 190

Thr Val Lys Glu His Thr Val Thr Thr Thr Lys Gly Glu Asn Phe
195 200 205

Thr Glu Thr Asp Ile Lys Met Met Glu Arg Val Val Glu Gln Met Cys
210 215 220

Val Thr Gln Tyr Gln Lys Glu Ser Gln Ala Tyr Tyr Asp Gln Gly Ala
225 230 235 240

Ser Val Ile Leu Phe Ser Ser Pro Pro Val Ile Leu Leu Ile Ser Phe
245 250 255

Leu Ile Phe Leu Ile Val Gly
260

<210> 12
<211> 264
<212> PRT
<213> Bos taurus

<400> 12

Met Trp Ser Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly
20 25 30

Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly
35 40 45

Gly Asn Arg Tyr Pro Pro Gln Gly Gly Gly Gly Trp Gly Gln Pro His
 50 55 60

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His
85 90 95

Pro Ser Lys Pro Lys Thr Asn Met Lys His Val Ala Gly Ala Ala Ala
 115 120 125

Ala Gly Ala Val Val Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala
 130 135 140

Met Ser Arg Pro Leu Ile His Phe Gly Ser Asp Tyr Glu Asp Arg Tyr
 145 150 - 155 160

Tyr Arg Glu Asn Met His Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro
 165 170 175

Val Asp Gln Tyr Ser Asn Gln Asn Asn Phe Val His Asp Cys Val Asn
180 185 190

Ile Thr Val Lys Glu His Thr Val Thr Thr Thr Lys Gly Glu Asn
195 200 205

Phe Thr Glu Thr Asp Ile Lys Met Met Glu Arg Val Val Glu Gln Met
210 215 220

Cys Ile Thr Gln Tyr Gln Arg Glu Ser Gln Ala Tyr Tyr Gln Arg Gly
225 230 235 240

Ala Ser Val Ile Leu Phe Ser Ser Pro Pro Val Ile Leu Leu Ile Ser
245 250 255

Phe Leu Ile Phe Leu Ile Val Gly
260

<210> 13
<211> 255
<212> PRT
<213> Ovis aries

<400> 13

Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val Ala
1 5 10 15

Met Trp Ser Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly
20 25 30

Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly
35 40 45

Asn Arg Tyr Pro Pro Gln Gly Gly Gly Trp Gly Gln Pro His Gly
50 55 60 80

Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His Gly
65 70 75 80

Gly Ser Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Gly Gly
85 90 95

Ser His Ser Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn Met Lys
100 105 110

His Val Ala Gly Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly
 115 120 125

Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Leu Ile His Phe Gly
 130 135 140

Asn Asp Tyr Glu Asp Arg Tyr Arg Glu Asn Met Tyr Arg Tyr Pro
 145 150 155 160

Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln Tyr Ser Asn Gln Asn Asn
 165 170 175

Phe Val His Asp Cys Val Asn Ile Thr Val Lys Gln His Thr Val Thr
 180 185 190

Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp Ile Lys Ile Met
 195 200 205

Glu Arg Val Val Glu Gln Met Cys Ile Thr Gln Tyr Gln Arg Glu Ser
 210 215 220

Gln Ala Tyr Tyr Gln Arg Gly Ala Ser Val Ile Leu Phe Ser Ser Pro
 225 230 235 240

Pro Val Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly
 245 250 255

<210> 14
 <211> 256
 <212> PRT
 <213> Ovis aries

<400> 14

Met Val Lys Ser His Ile Gly Ser Trp Ile Leu Val Leu Phe Val Ala
 1 5 10 15

Met Trp Ser Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly
 20 25 30

Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly
 35 40 45

Gly Asn Arg Tyr Pro Pro Gln Gly Gly Gly Trp Gly Gln Pro His
 50 55 60

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Pro His
65 70 75 80

Gly Gly Gly Trp Gly Gln Pro His Gly Gly Gly Trp Gly Gln Gly
85 90 95

Gly Ser His Ser Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn Met
100 105 110

Lys His Val Ala Gly Ala Ala Ala Ala Gly Ala Val Val Gly Gly Leu
115 120 125

Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Leu Ile His Phe
130 135 140

Gly Asn Asp Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn Met Tyr Arg Tyr
145 150 155 160

Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln Tyr Ser Asn Gln Asn
165 170 175

Asn Phe Val His Asp Cys Val Asn Ile Thr Val Lys Gln His Thr Val
180 185 190

Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr Asp Ile Lys Ile
195 200 205

Met Glu Arg Val Val Glu Gln Met Cys Ile Thr Gln Tyr Gln Arg Glu
210 215 220

Ser Gln Ala Tyr Tyr Gln Arg Gly Ala Ser Val Ile Leu Phe Ser Ser
225 230 235 240

Pro Pro Val Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly
245 250 255

<210> 15
<211> 254
<212> PRT
<213> Mus musculus

<400> 15

Met Ala Asn Leu Gly Tyr Trp Leu Leu Ala Leu Phe Val Thr Met Trp
1 5 10 15

Thr Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro Gly Gly Trp Asn
20 25 30

Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly Asn Arg
35 40 45

Tyr Pro Pro Gln Gly Gly Thr Trp Gly Gln Pro His Gly Gly Gly Trp
50 55 60

Gly Gln Pro His Gly Gly Ser Trp Gly Gln Pro His Gly Gly Ser Trp
65 70 75 80

Gly Gln Pro His Gly Gly Trp Gly Gln Gly Gly Thr His Asn
85 90 95

Gln Trp Asn Lys Pro Ser Lys Pro Lys Thr Asn Leu Lys His Val Ala
100 105 110

Gly Ala Ala Ala Ala Gly Ala Val Val Gly Gly Leu Gly Gly Tyr Met
115 120 125

Leu Gly Ser Ala Met Ser Arg Pro Met Ile His Phe Gly Asn Asp Trp
130 135 140

Glu Asp Arg Tyr Tyr Arg Glu Asn Met Tyr Arg Tyr Pro Asn Gln Val
145 150 155 160

Tyr Tyr Arg Pro Val Asp Gln Tyr Ser Asn Gln Asn Asn Phe Val His
165 170 175

Asp Cys Val Asn Ile Thr Ile Lys Gln His Thr Val Thr Thr Thr Thr
180 185 190

Lys Gly Glu Asn Phe Thr Glu Thr Asp Val Lys Met Met Glu Arg Val
195 200 205

Val Glu Gln Met Cys Val Thr Gln Tyr Gln Lys Glu Ser Gln Ala Tyr
210 215 220

Tyr Asp Gly Arg Arg Ser Ser Ser Thr Val Leu Phe Ser Ser Pro Pro
225 230 235 240

Val Ile Leu Leu Ile Ser Phe Leu Ile Phe Leu Ile Val Gly
245 250

<210> 16
<211> 8
<212> PRT
<213> Mus musculus

<400> 16

Gly Gly Gly Trp Gly Gln Pro His
1 5

<210> 17
<211> 8
<212> PRT
<213> Mus musculus

<400> 17

Gly Gly Ser Trp Gly Gln Pro His
1 5

<210> 18
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 18
tccatgacgt tcctgacgtt

20

<210> 19
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic oligonucleotide

<400> 19
tcgtcgaaaa gtcgttttgt cgtt

24

THIS PAGE BLANK (USPTO)